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Glioblastoma multiforme (GBM) is the common and malignant form of adult primary brain 
tumor, often with poor prognosis. Survival of patients remains dismal despite surgical intervention 
and adjuvant therapies (chemo- and radiation therapies). There is thus an unmet need to design new 
therapies that significantly improve patient outcomes. Furthermore, treatment strategies have been 
complicated by intrinsic intratumoral heterogeneity driven by clonal evolution with distinct genomic 
aberrations. Using lineage tracing mouse models, neural stem cells have been identified as the cells-
of-origin, thus supporting the cellular hierarchy model of GBM development. While patient-derived 
GBM-propagating cells (GPCs) cannot identify the cell-of-origin, we and others have demonstrated 
that: (i) GPCs possess extensive self-renewing and serial tumor-propagating activity; (ii) They exhibit 
karyotypic aberrations typically found in the primary tumor; and (iii) They reform tumor xenografts 
that recapitulate the patient’s original histopathology and molecular fingerprint. These findings 
suggest that patient-derived GPCs are important and clinically relevant. 
 To decipher the regulatory cues of GPCs, we executed a small molecule screen in high 
throughput manner, using candidate compounds that targeted various central oncogenic pathways 
important in GBM growth. Subsequently, upon selection of potential compounds, we refined our 
approach using neurosphere assays to detect long-term, self-renewal of slow-growing GPCs. These 
assays are distinct from traditional short-term, viability-based methods used in typical drug screens 
which often mask the effects of the minority GPCs. It is important to determine that the small 
molecules target both bulk cells constituting the tumor and GPCs for an effective cure. Using a 
combination of pharmacological and genetic approaches, we showed that PLK1 inhibition led to 
significant reduction in self-renewing spheres (GPC frequency), sphere size (proliferation), and 
effected G2/M cell cycle arrest with concomitant apoptosis. Additionally, GPCs were induced to 
differentiation upon BI2536 treatment, suggesting a possible method for inducing tumor involution as 
a potential treatment strategy. Importantly, when mice bearing subcutaneous tumor xenografts were 
intravenously treated with BI2536, a well-documented PLK1 inhibitory small molecule currently in 
clinical trials, tumor volume was significantly reduced compared to vehicle-treated mice. These data 
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provide strong support that PLK1 regulates GPC survival and consequently tumor growth, and is a 
viable therapeutic target. 
 In recognizing the experimental design limitations of patient-derived GPCs, we tapped into 
bioinformatics analyses utilizing large, independent patient glioma databases: REMBRANDT and 
Gravendeel. We found that high PLK1-coexpressed genes stratified patients for poor survival, 
independent of current clinical indicators such as age and tumor grade. Interestingly, the high PLK1-
coexpressed module is enriched in core stem cell programs. Collectively, our findings emphasize the 
molecular heterogeneity of GBM, and the limitations of diagnosis depending solely on morphology-
based histological methods to diagnose and subsequently treat patients. We show that GPCs are 
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CHAPTER 1- INTRODUCTION 
 
 Brain tumors comprise all tumors arising from within the cranium or central nervous system1. 
These neoplasms can arise from any aberrant cellular proliferation within the brain itself, or even 
abnormality in lymphatic tissue, blood vessels, meninges or even glands within the skull. While there 
are over 120 types of brain tumors, the most common and malignant subtypes are represented by 
gliomas of glial cell origin. Despite advanced surgical intervention and chemotherapeutic treatment 
with radiation, gliomas such as glioblastoma multiforme (GBM, grade IV) present the worst 
prognosis, often with a mean survival period of 15 months post-diagnosis. Consequently, there is a 
need to develop better therapeutic strategies to target the highly aggressive and infiltrative nature of 
the disease. The recurrent nature of GBM has in recent years been shown to arise from stem-like 
neural precursor cells2-4. These cells display extensive self-renewal capacity and are able to 
differentiate into all 3 neural lineages (astrocytes, neurons, oligodendrocytes), thus reforming the 
tumor mass. In addition, they also possess protective mechanisms that endow the cells with 
chemoresistant and radioresistant traits5-7. While neural stem cells and oligodendrocyte progenitor 
cells have been shown to initiate and sustain tumors using transgenic mouse models8-10, their cell-of-
origin in patient-derived glioma-propagating cells (GPCs) remains unclear. Nevertheless, in vitro 
cultured GPCs remain clinically relevant for several reasons: (i) They contain phenotypic, 
transcriptomic and karyotypic information that mirrors the original patient tumor11-12; (ii) They re-
establish orthotopic tumor xenografts that recapitulate the patient’s original histopathology; and (iii) 
GPC-derived gene signatures contribute to disease progression and patient survival outcome 
independently of current clinical indicators such as age and histology13-14, thereby underscoring the 
limitations of relying solely on morphology-based methods to diagnose and subsequently treat 
patients. These properties make GPCs a very attractive cellular tool for drug screening. However, 
because GPCs are slow-growing and are often a minority cellular subset, new endpoint measures need 
to be designed in such drug screens, which routinely rely on short-term viability assays. This forces a 
re-evaluation of criteria to define GPC activity15, i.e. they must exhibit long-term self-renewal and the 
ability to form tumors that phenocopy the original primary tumor. Our work here describes the use of 
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GPCs in a small molecule screen to identify novel regulatory pathways, and we characterize a 
candidate gene, PLK1 as a molecular target. Furthermore, we employ bio-informatical approaches to 
study the contribution of PLK1-associated pathways to patient survival and tumor progression. 
Collectively, our work sheds light on the role of PLK1 in gliomas. 
 
1.1. Glioma classification 
1.1.1. World Health Organization (WHO) grading 
 Histological grading is a means of predicting the biological behavior of a neoplasm. In the 
clinical setting, tumor grade is a key factor influencing the choice of therapies, particularly 
determining the use of adjuvant radiation and specific chemotherapy protocols. The WHO 
classification of tumors of the nervous system includes a grading scheme that is a “malignancy scale” 
ranging across a wide variety of neoplasms rather than a strict histological grading system16-17. It is 
widely used, but not a requirement for the application of the WHO classification.  
 
1.1.2. Grading across tumor entities 
 Grade I applies to lesions with low proliferative potential and the possibility of cure following 
surgical resection alone. Neoplasms designated grade II are generally infiltrative in nature and, despite 
low-level proliferative activity, often recur. Some type II tumors tend to progress to higher grades of 
malignancy, for example, low-grade diffuse astrocytomas that transform to anaplastic astrocytoma 
and glioblastoma. Similar transformation occurs in oligodendroglioma and oligoastrocytomas. The 
designation WHO grade III is generally reserved for lesions with histological evidence of malignancy, 
including nuclear atypia and brisk mitotic activity. In most settings, patients with grade III tumors 
receive adjuvant radiation and/or chemotherapy. The designation WHO grade IV is assigned to 
cytologically malignant, mitotically active, necrosis-prone neoplasms typically associated with rapid 
pre- and postoperative disease evolution and a fatal outcome. Glioblastoma is an example of a grade 
IV disease. Widespread infiltration of surrounding tissue and a propensity for craniospinal 
dissemination characterize some grade IV neoplasms. 
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1.1.3. Grading of astrocytic tumors 
 Grading has been systematically evaluated and successfully applied to a spectrum of diffusely 
infiltrative astrocytic tumors. These neoplasms are graded in a three-tiered system similar to that of 
the Ringertz18, St Anne-Mayo19 and the previously published WHO schemes17. The WHO defines 
diffusely infiltrative astrocytic tumors with cytological atypia alone as grade II (diffuse astrocytoma), 
those also showing anaplasia and mitotic activity as grade III (anaplastic astrocytoma), and tumors 
additionally showing microvascular proliferation and/or necrosis as WHO grade IV. This system is 
similar to the St Anne/Mayo classification19, with the only major difference being grade I; in the 
WHO system, grade I is assigned to the more circumscribed pilocytic astrocytoma, whereas the St 
Anne/Mayo classification assigns grade 1 to an exceedingly rare diffuse astrocytoma without atypia. 
Since the finding of a solitary mitosis in an ample specimen does not confer grade III behavior, 
separation of grade II from grade III tumors may be more reliably achieved by determination of MIB-
1 labeling indices20-22. For WHO grade IV, some authors accept only the criterion of endothelial 
proliferation, i.e. an apparent multi-layering of endothelium. The WHO classification also accepts 
glomeruloid microvascular proliferations. Necrosis may be of any type; perinecrotic palisading need 
not be present. 
 
1.1.4. Tumor grade as a prognostic factor 
 WHO grade is one component of a combination of criteria used to predict a response to 
therapy and outcome. Other criteria include clinical findings, such as age of the patient, neurologic 
performance status and tumor location; radiological features such as contrast enhancement; extent of 
surgical resection; proliferation indices; and genetic alterations. For each tumor entity, combinations 
of these parameters contribute to an overall estimate of prognosis. Despite these variables, patients 
with WHO grade II tumors typically survive more than 5 years and those with grade III tumors 
survive 2–3 years. The prognosis of patients with WHO grade IV tumors depends largely upon 
whether effective treatment regimens are available. The majority of glioblastoma patients, particularly 
the elderly, succumb to the disease within a year. For those with other grade IV neoplasms, the 
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outlook may be considerably better. For example, cerebellar medulloblastomas and germ cell tumors 
such as germinomas, both WHO grade IV lesions, are rapidly fatal if untreated, while state-of-the-art 
radiation and chemotherapy result in 5-year survival rates exceeding 60 and 80%, respectively. 
 
1.2. Molecular heterogeneity of gliomas and the application of bioinformatical approaches 
 In 2006, the National Cancer Institute initiated an effort to deep profile, as one of the first 
cancers, glioblastoma multiforme, because of its dismal prognosis despite advanced surgical 
intervention and adjuvant chemotherapy and radiation treatment. This effort is predicated on the belief 
that histologically similar tumors can be molecularly heterogeneous, and that distinct pathways drive 
the biological phenotype. The first publication arising from The Cancer Genome Atlas (TCGA) effort 
showed that patients with GBM sustain mutations that can be grouped into three major signaling 
networks23: Receptor tyrosine kinases (RTKs), p53 and Retinoblastoma tumor suppressor pathways. 
Importantly, GBM tumors are molecularly heterogeneous, further highlighting the limitations of 
relying solely on morphology-based histological methods to diagnose and subsequently treat patients. 
A follow-up study then showed that GBM tumors can be molecularly classified into four subgroups 
(Proneural, Classical, Mesenchymal, Neural)24, with each subgroup containing unique gene 
expression, genomic aberrations and clinical profile. A major inference from such studies is that GBM 
patients can now potentially be treated according to their molecular subclasses and pathway 
activation. Indeed, Wiedemeyer et al.25 recently showed through pharmacological targeting in a panel 
of GBM cell lines that co-deletion of CDKN2A and CDKN2C served as a strong predictor of 
sensitivity to a selective inhibitor of CDK4/6. This mapped to similar patterns of CDKN2A and 
CDKN2C mutations in TCGA patients, leading to hyperactivated CDK4/6. The Wiedemeyer study 
thus demonstrates that the integration of genomic, functional and pharmacologic data can be exploited 
to inform the development of targeted therapy directed against specific cancer pathways. Importantly, 




 In assessing the contribution of GPCs to the primary tumor phenotype, several studies have 
focused on analyzing common GPC marker expression in tissue paraffin sections, often with 
ambiguous data. This may be reconciled by the fact that GPC properties that sustain the tumor 
phenotype may reside in more than just specific marker profiles4,26-29. Consequently, pathway 
activation resembling those functioning in stem-like cells, represented by a set of genes, is more likely 
to correctly interrogate the clinical contribution of GPCs. An elegant study was carried out by 
Visvader and colleagues in BRCA1 mutation-associated breast tumors30. The authors derived 
differentially regulated genes in subsets of epithelial cells and found that luminal progenitors were 
highly represented in BRCA1 mutation-associated basal tumors, even more than the commonly 
anticipated stem cell population. This suggests that luminal progenitors are more likely the cells-of-
origin for BRCA1 mutation-associated breast cancers, later confirmed in a transgenic mouse model 
study. Such studies underscore the predictive ability of gene expression mapping of pathway 
activation, rather than focus on a specific marker identity. Separately, John Dick and colleagues 
recently demonstrated that serial tumor-propagating (and not marker-defined) acute myeloid leukemia 
stem cells contribute to disease progression and patient survival outcome31, highlighting the 
importance of functionally defining the cancer stem cell. Two other more relevant studies 
demonstrated that GPCs contribute to GBM patient survival outcome, with preferential activation of 
core stem cell programs (hematopoietic, neural and embryonic stem cells)14,32. The key message from 
such studies is that cancer stem cells perpetuate tumors not merely in terms of their cell numbers, but 
more accurately reflected by their pathway activation. Consequently, the primary tumor phenotype is 









1.3. Animal models of glioma 
As previously discussed, high-grade gliomas are heterogeneous tumors both at the molecular 
and cellular levels. The complex biology of these tumors makes understanding glioma pathogenesis 
and the development of novel effective therapies extremely challenging. While using established 
glioma cell lines or primary glioma cultures to study glioma biology or test novel drugs in vitro can be 
of some benefit33-35, these studies lack the ability to address the more complex issues related to 
gliomagenesis, the role of the tumor stroma and drug pharmacodynamics (i.e., efficacy and toxicity). 
Over the years, a number of strategies for creating in vivo mouse models of glioma have been 






Table-1. Mouse models of glioma   
  








glioma cell lines into 
athymic rodents 
 Low breeding costs  
 Large numbers of tumor 
bearing mice can be 
generated 
 Bioluminescence 
monitoring of tumor 
growth 















of human glioma cells 
into athymic rodents 
 More accurately mimics 
the response to therapy of 
human glioma 











Mice harboring genetic 
alterations that allow for 
gliomagenesis de novo 
 Molecular and 
histologically similar to the 
human disease 
 Tumor-host immunological 
response intact 
 Several short latency high 
penetrance models are 
available 
 Bioluminescence 
monitoring of tumor 
growth 




1.3.1. Xenograft models 
 Classic xenograft models are generated by subcutaneously or orthotopically implanting 
established and commonly serum-grown, human glioma cell lines into athymic mice. 
Bioluminescence and green fluorescent protein have aided the utility of these models for drug 
discovery by allowing the visualization of tumors in vivo36-39. U87MG is one serum-grown, human 
cell line that has been used extensively because of the high rate of tumor take after implantation and 
the short survival time. A number of studies have been conducted using U87MG cells to assess the 
pharmacokinetics and treatment efficacy of a variety of novel therapies40-41. While this model provides 
a straight forward in vivo approach to preclinical testing, the major drawback of using cell lines is the 
lack of histologic similarity to the human disease42. These models have been of limited utility in 
predicting the efficacy of novel therapies in humans when used in preclinical studies43-44. Other 
xenograft models have been developed by taking tumor cells directly from the patient, or GPCs grown 
in serum-free condition, and implanting them into athymic mice resulting in a more invasive 
phenotype2. Genetically and histologically accurate models of human glioma have also been 
developed through creating genetically engineered mouse models (GEMMs) which appear to be the 
best models to date for investigating glioma pathogenesis. GEMMs of glioma can exhibit a similar 
survival response to therapy as patients and thus may be useful models in preclinical studies43.  
 
1.3.2. Genetically  engineered model of glioma 
 Carcinogenesis is a process involving serial mutagenic events in genes involved in cell 
proliferation, survival and invasion. Human cancers primarily occur somatically and the cell type of 
origin dictates the character of the resulting tumor45. GEMMs that possess germ-line modifications of 
well-established oncogenes are usually heterozygous at the gene locus of interest as homozygous loss 
is often embryonic lethal. In these models, spontaneous loss of the second allele leads to tumor 
formation46-47. Thus, many germline transgenic models tend to be more reflective of a human tumor 
predisposition syndrome where the threshold for transformation is lower. Germ-line models can be 
combined with ‘conditional’ systems to allow for tumor induction in a temporal-spatial manner48-49. 
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The use of the Cre-Lox and RCAS/tv-a systems are two examples of this approach. The Cre-Lox 
system allows for targeted deletion of a gene flanked by loxP sites (derived from the P1 
bacteriophage) within a specific cell type when Cre recombinase is expressed under the control of the 
tissue-specific promoter. The replication competent avian leukosis virus splice acceptor (RCAS) viral 
vector can be used to deliver a gene of interest into targeted brain cells when the expression of TVA 
(avian leukosis virus receptor A; the RCAS receptor) is driven by a tissue-specific promoter50. 
Additionally, mice harboring germline aberrations in tumor suppressor genes such as INK4a/ARF 
have a decreased threshold for tumor formation and develop high penetrant malignant gliomas when 
additional tumor inducing lesions are introduced51. GEMMs have been developed by over-expressing 
components of signal transduction pathways that promote cell proliferation and survival. Disrupting 
normal function of components of the P13K/AKT/mammalian target of rapamycin and RAS/MAPK 
signaling pathways through aberrations in receptor tyrosine kinases or their ligands (i.e. EGFR and 
PDGF), over-expressing protein kinases (i.e. AKT, RAS) or by loss of tumor suppressors (i.e. NF1, 
TP53, Rb) can contribute to glioma formation. Although over-expression of AKT and RAS is 
observed in the human disease, it is not a result of a direct gene effect. Instead, gene over-expression 
is the result of the activation of upstream receptor tyrosine kinases and their ligands. Perhaps the more 
relevant models of glioma are those that model the newly identified molecular subclasses of human 
glioma. Generally speaking, these GEMMs can be considered as accurate models of the signaling 
abnormalities that occur in human glioma; however, one could argue that they simply confirm 
causality of tumor formation. It should be noted that even though glioma formation is driven by 
molecular anomalies that define the human subtypes (i.e., PDGF, EGFR, NF1), it is not yet known to 
what extent these tumors harbor other molecular characteristics contained in the subclasses that they 
theoretically represent. Recent gene expression studies of gliomas isolated from GEMMs have 






1.4. Re-defining assay criteria for detecting GPCs 
 In our study, we sought to determine signaling pathways that regulate GPC survival, since 
they would be the most likely culprits of tumor recurrence. Specifically, we looked for compounds 
that could inhibit these GPCs, cultured in vitro as spherical structures. Conventional tumor cell 
screening typically involves short-term viability readouts of adherent, monolayer cells upon drug 
treatment. Undoubtedly, the use of serum-grown glioma cell lines facilitates drug screens due to their 
fast-growing nature. Also, phenotypic screens such as high content screening can be applied to these 
adherent monolayer cells. However, the use of these serum-grown glioma cells has to be taken with 
caution as they have been found to possess pronounced phenotypic and transcriptomic differences 
distinct from their primary tumors54. In dealing with GPCs, we recognized that bona fide self-renewal 
in slow-growing cells cannot be accurately detected in short-term viability assays as the latter also 
measure other transient-amplifying progenitors in the heterogeneous spheres55. Consequently, 
parameters such as sphere number over serial passages which reflects GPC frequency, and sphere size 
which indicates GPC-specific proliferation are measured. Sphere activity often correlates with in vivo 
tumor-initiating and sustaining capacity, thus is a reliable in vitro factor to monitor especially in the 
subset of GPCs that confer self-renewal with concomitant tumor-propagating ability. The extended 
period of such screens often complicates the experimental procedure, since regular replenishment of 
growth factors must take place to sustain the relatively undifferentiated state of GPCs as otherwise, 
induction of differentiation leads to loss of tumorigenic potential56. Additionally, we adapted the 
sphere assay to measure residual self-renewing activity upon drug removal from the medium over an 
extended period. This step would indicate if GPC frequency has been altered for a long-lasting 
inhibition. Of note, we identified several known regulators of GPC maintenance, as well as a 







1.5. PLK1 regulation and physiological role 
1.5.1.  PLK1 regulation 
PLK1 is involved in multiple roles during mitosis57-59. The general protein structure of all 
members of the Polo-like kinase family consists of an amino-terminal Serine/Threonine catalytic 
kinase domain and a carboxyl-terminal Polo-box domain (Figure-1). The expression, activity and 
cellular localization of PLK1 are strictly regulated throughout cell cycle, with its activity peaking 
during G2/M phase. Accordingly, PLK1 can be regulated at 2 levels; namely at transcriptional level 
during G0-G1 phase where PLK1 expression repressed60-62, or at protein level63. In the regulation of 
PLK1, published literature has implicated the CDE/CHR (cell-cycle-dependent element/cell cycle 
gene homology region)62 and  retinoblastoma tumor suppressor (RB) pathway64. To-date, the 
mechanism behind repression of PLK1 is largely unclear, although published literature has suggested 
CDF-1 (CDE/CHR binding factor1) in repression PLK1 transciption61. Alternatively, the expression 
of p53-inducible cell cycle inhibitor p21WAF21/CIP1/SDI1 has also been shown to interact with CDE/CHR, 





In the Rb pathway, PLK1 repression is partially dependent on the E2F transcription factor 
family; specifically, E2F4, a repressor E2F64. E2F proteins have been established as important 
regulators of cell cycle, whereby their interaction with Rb proteins result in G0-G1 repression of 
promoters alongside histone deacetylases66-67. Furthermore, Rb-mediated suppression of PLK1 is been 
found to be dependent on SWI/SNF, a heterogeneous multi-subunit chromatin remodeling complex64 
(Figure-2).  It was shown that loss of SWI/SNF does not disrupt the interactions of the Rb pocket 
Figure-1. Domains of PLK1 protein. The N-terminal kinase domain spans from amino acid 
residues 53 to 305 while C-terminal Polo-Box domain spans from residues 407 to 594. 
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proteins (p107 and p130) and E2F4 at the PLK1 promoter. Hence, the depletion of SWI/SNF 
abrogates Rb pathway suppression of PLK1 in a hierarchical manner whereby: (1) The histone 
deacetylase fails to be recruited at the promoter, and (2) chromatin remains in the relaxed 
conformation for continuous transcription.  
Another candidate known to positively regulate PLK1 expression throughout cell cycle is 
FoxM1 (Foxhead Box M1)68. FoxM1 is a known substrate of PLK1 during cell division. The initial 
activation of FoxM1 is initiated by cyclin dependent kinase 1(CDK1), which enables binding to the 
polo-box domain (PBD) of PLK1, hence forming a complex where it gets hyperphosphorylated. 
Subsequently, FoxM1’s transcriptional activity is activated and leads to an increase of expression of 
several mitotic regulators. PLK1 and FoxM1 work synergistically, creating a positive feedback loop 
which enhances each other’s activity. 
            
 
 
At protein level, PLK1 kinase activity highly depends on the activation of its catalytic domain 
at the threonine 210 (Thr210) residue57,63,69. Under normal circumstances, the structural conformation 
of PLK1 auto-inhibits itself and its subsequent activation requires cooperation between both Aurora 
kinase A (AurkA) and Bora. Briefly, the polo-box binding domain (PBD) of PLK1 interacts with its 
own kinase domain, forming a T-loop that hinders AurkA from accessing Thr210. As Bora binds to 
the PBD of PLK1, auto-inhibition is relieved and AurkA gains access to initiate phosphorylation on 
Thr210. Thereafter, PLK1 executes a series of phosphorylation events pertinent to mitosis; for 
Figure-2. Schematic diagram of PLK1 transcriptional regulation. In SWI/SNF-deficient cells, 
E2F4 and pocket proteins can still be recruited to PLK1 promote while histones remain acetylated and 
the promoter retains activity. On the contrary, in the presence of SWI/SNF, recruitment of E2F4 and 
pocket proteins leads to deacetylation at PLK1 promoter, and therefore promoter repression.  
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example, activation of cyclin dependent kinase 1 (Cdk1). Alongside, the activated PLK1 migrates to 
respective mitotic machinery to take on its role in cell cycle. 
 
1.5.2.  Physiological role of PLK1 
At the onset of cell division, PLK1 assumes multiple essential roles to maintain normal 
mitosis (Figure-3). Of note, PLK1 localization is observed to be highly dynamic during cell division. 
The PBD has been found to be important in localizing the protein70-71. Inhibition of PBD using 
Poloxin, a synthetic derivative of thymoquinone presents severe impacts on cell cycle following 
mislocalization of PLK1, for instance, chromosome congression defects, mitotic arrest and apoptosis. 
A brief summary of PLK1’s involvement is as follows: 
i. M phase entry and G2 DNA checkpoint:  
 PLK1 initiates mitotic entry by activating Cdc25C72-73 and inhibiting Wee1/Myt1. This results 
in the activation the Cyclin B/Cdk1 complex which in turn initiates mitosis. PLK1 activity is known 
to be inhibited after DNA damage74. Some targets of PLK1 involved in this checkpoint includes p5375 
and BRCA276 (breast cancer susceptibility protein, essential for DNA repair). Under normal 
conditions, these proteins are inhibited by PLK1 through phosphorylation. To proceed on, PLK1 
activity is essential to repress their inhibition. 
ii. Centrosome maturation and bipolar spindle formation: 
 Centrosome maturation needs PLK1 for the recruitment of various proteins such as γ-tubulin 
and also its separation to establish proper bipolar spindle77. The phosphorylation of the centrosome 
protein, Nlp by PLK1 is essential for microtubule nucleation, which otherwise, leads to failure in the 
formation of the mitotic spindle78. Also, PLK1 is found to phosphorylate α, β and γ-tubulins and the 
tubulin-stabilizing protein (TCTP)79-80.  Collectively, PLK1 is required for establishment of bipolar 
spindle and regulates the activity of tubulins. 
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iii. Separation of sister chromatids: 
 Sister chromatids are kept intact by cohesin81 till anaphase occurs. The phosphorylation of 
cohesin by PLK1 occurs twice during mitosis. At prophase (early mitosis), the cohesin subunit, SA2, 
is phosphorylated to allow dissociation from chromosome. Later on at the metaphase-anaphase 
juncture, PLK1 phosphorylates the cohesin subunit, Scc1, hence aiding its cleavage by separase. 
iv. Chromosome alignment and kinetochore function: 
 PLK1 has been implicated in chromosome alignment as its mislocalization causes incomplete 
lining-up of chromosomes at the metaphase plate82. Furthermore, PLK1 has been shown to be 
involved in the stabilization of microtubule-kinetochore interactions and also the recruitment of 
kinetochore proteins such as Hec1/Ndc80 which aids in the attachment of microtubules to kinetochore 
at metaphase83. 
v. Activating Anaphase Promoting Complex/cyclosome (APC/C) and cytokinesis: 
 APC/C, an E3 ubiquitin ligase, is activated at metaphase-anaphase juncture once spindle 
checkpoint is cleared with proper alignment of chromosomes at the metaphase plate and attached to 
microtubules. PLK1 activates APC/C by two ways: (1) Phosphorylating subunits of APC/C, and (2) 
inducing destruction of Emi1, an APC/C inhibitor. The active APC/C promotes exit of cell division by 
initiating degradation of Cyclin B/Cdk1, also, by releasing separase that aids in sister chromatid 
separation. 
 At cytokinesis, PLK1 activity is important for proteins such as NudC (nuclear distribution 
gene C), MKlp2 (myosin kinase like protein 2) and RhoGEF ECT2 (Rho guanine nucleotide exchange 




                     
 
 
1.5.3. PLK1 and tumors 
Elevation of PLK1 has been reported in several forms of cancers86-91 and its upregulation has 
been proposed as a negative prognostic factor of the disease92-94. Given that PLK1 is heavily involved 
in mitosis, deregulation of PLK1 would inevitably result in mitotic catastrophe with the formation of 
multinucleated cells. Initial work has presented low levels of PLK1 mRNA in mature cells such as the 
heart, lung, brain, liver, kidney, pancreas and skeletal muscles95. On the contrary, mitotically active 
normal cells derived from the colon and placenta show higher expression of PLK1, hence highlighting 
that only proliferating cells possess elevated PLK1 levels. Subsequently, Smith et al.96 demonstrated 
the malignant transformation of normal NIH 3T3 cells with over-expression of PLK1. Furthermore, 
PLK1 is also known to inhibit the p53 tumor suppressor via phosphorylation, therefore repressing the 
activation of p53-mediated apoptosis. Collectively, these observations support the notion of over-
expression of PLK1 as a cause of tumorigenesis, instead of the effect of tumorigenesis.  
Figure-3. Schematic diagram illustrating the multiple roles of PLK1 during cell division. PLK1 
activity is important at the various phases of mitosis to ensure proper cell division. It also serves as 
gatekeeper at both G2/M phase DNA-damage checkpoint and spindle checkpoint. 
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Alternatively, PLK1 depletion potentially results in tumorigenesis too. Previously, missense 
mutations of PLK1 within its PBD were found to disrupt the interaction between PLK1 and HSP9097. 
HSP90 is a molecular chaperon vital for protein folding98. As a result, PLK1 expression is reduced 
due to instability of its mutant protein. Consequently, the PLK1 depletion inevitably contributes to 
mitotic defects and ultimately leading to tumorigenesis.  
 
1.6. Scope of study 
1.6.1 Hypothesis 
We hypothesize that GPCs can be eradicated by targeting their regulatory pathways, resulting 
in tumor involution and long-lasting inhibition. Patients who demonstrate activation of such 
regulatory pathways through genomewide transcriptomic changes correlate with poor prognosis, and 
are likely more amenable to such pathway inhibitory small molecules.  
 
1.6.2 Objectives 
We will present a case study of a small molecule screen conducted with GPCs and explain 
how unique sphere activity assays were implemented to distinguish drug efficacies against the long-
term, self-renewing fraction, as opposed to transient-amplifying progenitors, latter of which are 
detected in conventional viability assays. We identified Polo-like kinase 1 as a novel regulator of GPC 
survival. Finally, we will leverage on public glioma databases to illustrate GPC contribution to 
disease progression and patient survival outcome. Our study sheds light on the role of PLK1 in 
maintaining the brain tumor stem cell population, and combines bioinformatical approaches to 
interrogate PLK1-associated biological pathways in clinical databases. We provide evidence to 





CHAPTER 2 - MATERIALS AND METHODS 
 
2.1. Cell culture 
2.1.1.  Tissue collection and GPC neurosphere culture 
Graded clinical brain tumor specimens (NNI-1, 4, 5, 8, and 12) were obtained through 
informed consent as part of a study protocol approved by the institutional review board. In this study, 
NNI-1 was from a patient with recurrent GBM (Grade IV) and had received radiation therapy, while 
NNI-4 and NNI-5 were from patients with primary GBM and treatment-naïve. Tumor samples were 
processed using methods established in our previous work99. Cells were seeded as free-floating 
spheres at a density of 2,500 cells per cm2 in chemically defined serum-free selection growth medium 
consisting of basic fibroblast growth factor (bFGF, 20 ng/ml, PeproTech, New Jersey), epidermal 
growth factor (EGF, 20 ng/ml, PeproTech), heparin (5 µg/ml; Sigma-Aldrich, St Louis), and serum-
free supplement (B27, 1x, Gibco, Grand Island, NY) in a 3:1 mix of Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma-Aldrich) and Ham’s F-12 Nutrient Mixture (F-12, Gibco). Also, final 
concentrations 100 Units/ml Penicillin-Streptomycin, 1 mM Non-Essential Amino Acid (NEAA, 
Gibco) and 1 mM Sodium Pyruvate (Gibco) were added. The cultures were incubated at 37oC in a 
water-saturated atmosphere containing 5% CO2 and 95% air. To maintain the undifferentiated state of 
neurosphere cultures, growth factors were replenished every 2-3 days. Cultures were expanded by 
mechanical trituration using flame-drawn glass Pasteur pipettes, and cells were re-seeded at 100,000 
cells per millilitre in fresh medium supplemented with growth factors. 
 
2.1.2.  ATCC glioma cell cultures 
Human glioma cell lines (U251, T98G and U87-MG) and mouse astrocyte (C8-D1A) were 
purchased from ATCC (American Type Cell Culture, California, USA). Cells were maintained as 
adherent monolayer cultures in DMEM supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 
together with Penicillin-Streptomycin, NEAA and Sodium Pyruvate. 
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Lenti-X 293T, a sub-clone of the transformed human embryonic kidney cell line, HEK 293, 
was purchased from Clontech (Clontech, California, USA). Cells were maintained as adherent 
monolayer cultures in DMEM supplemented with 10% FBS (Gibco) and 1mM Sodium Pyruvate 
(Gibco). The cultures were incubated at 37oC in a water-saturated atmosphere containing 5% CO2 and 
95% air. 
 
2.1.3.  Normal Human Astrocytes (NHA) and Normal Human Neural Progenitor (NHNP) 
Both NHA and NHNP were purchased from Lonza (Lonza Incorporation; Allendale, New 
Jersey, USA). NHA cells were maintained as adherent monolayer cultures with Clonetics™ Astrocyte 
Cell System (Lonza), a serum-based culture condition, according to manufacturer’s instruction. 
NHNP cells were maintained as suspension cultures in Poietics™ Neural Progenital Cell System 
(Lonza), which is serum-free culture condition, according to manufacturer’s instruction. The cultures 
were incubated at 37oC in a water-saturated atmosphere containing 5% CO2 and 95% air. 
 
2.2. Cell viability assay 
2.2.1.  Determining half inhibitory concentrations (IC50) of BI2536  
BI2536 was purchased from Chemietek (Indianapolis, USA). GPC neurospheres were 
dissociated with AccutaseTM (eBIOscience Inc., San Diego) and seeded into 96-well plates, at a 
density of 2,000 cells per well, with DMEM/F12 medium supplemented with growth factors. The 
neurospheres were allowed to recover over 3-4 days prior to drug treatment. For ATCC glioma lines, 
cells were seeded at a density of 662 cells per well into 96-well plates and allowed to recover 
overnight prior to treatment. Cell viability after drug treatment was assessed using alamarBlue® 
(Serotec, Oxford, UK). Briefly, cells were incubated with 10% culture volume of alamarBlue® for 
approximately 16 hours before absorbance readings were measured at 570 and 600 nm. Dose response 
curves for each line were generated using GraphPad Prism (GraphPad Software Inc., USA) and IC50 




2.2.2.  High-throughput Screen  
GPC neurospheres were dissociated with AccutaseTM (eBIOscience Inc.) and seeded into 96-
well plates, at a density of 10,000 cells per well, with DMEM/F12 medium supplemented with growth 
factors. Cells were allowed to recover over 3-4 days prior to compound addition at 10 µm in HTS I or 
0.1 µm HTS II respectively. Cell viabilities after drug treatments were assessed using alamarBlue® 
(Serotec).  
 
2.2.3.  Viability of cells after shPLK1 transduction 
GPC neurospheres transduced with shPLK1 constructs were selected-out by replacing spent 
media with fresh complete media consisting 2 µg/ml puromycin (Sigma-Aldrich) at 72 hours after 
lentiviral transduction. Neurospheres were dissociated with AccutaseTM (eBIOscience Inc.) after 48 
hours of selection, stained with 7-Amino-Actinomycin Viability Dye D (7-AAD; BD Pharmingen™; 
USA), and seeded into 96-well plates, at a density of 2,000 live cells per well using BD FACSAria™ 
(BD Biosciences; New Jersey; USA) cell sorter.  Thereafter, cell viability was assessed using 
alamarBlue® (Serotec) at Day 10 and 20 after lentiviral transduction.  
ATCC glioma cell lines were lentivirally transduced for 48 hours prior to replacement with 
fresh media containing 2 µg/ml puromycin (Sigma-Aldrich). After 48 hours of puromycin selection, 
cells were harvested and re-seeded into 96-well plates at a density of 662 cells per well. Thereafter, 
cell viability was assessed by means of alamarBlue® (Serotec) at Day 5 and 10 after lentiviral 
transduction.  
 
2.2.4.  Viability assessment after PLK1 overexpression 
Lentiviral transduced GPCs were subjected to cell sorting based on mCherry fluorescence, at 
a density of 2,000 cells per well. Cells were allowed to recover for 1 day prior to BI2536 (Chemietek) 





2.3. Western blot analysis 
Cells were harvested and pelleted prior to lysis with lysis buffer [ 1x Igepal (Sigma Aldrich), 
10% glycerol (Sigma Aldrich), 2 mM EDTA, 0.15 M NaCl, 50 mM Tris-HCl pH 7.2, Complete Mini 
Protease Inhibitor Cocktail Tablets (Roche; Indianapolis; USA), Phostop Phosphatase Inhibitor 
Cocktail Tablet (Roche)]. Approximately 40 µg of heat denatured protein lystates were resolved on 
8% SDS polyacrylamide gel, transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, 
Darmstadt, Germany), and probed with the following primary antibodies: anti-PLK (1:1000, Life 
Technologies, #37-700), anti-tubulin, beta III isoform ( TuJ1, 1:1000, Millipore, MAB1637), anti-
Glial Fibrillary Acidic Protein (GFAP, 1:4000, Dako, Denmark, Z0334) and β-actin antibody 
(1:20000, Sigma Aldrich, AC-15). Goat anti-mouse horseradish peroxidase (HRP)-conjugated 
secondary antibody (1:10000, ECL Amersham Biosciences, Buckinghamshire, UK) or goat anti-rabbit 
horseradish peroxidase (HRP)-conjugated secondary antibody (1:10000, ECL Amersham Biosciences, 
Buckinghamshire, UK) were used. All antibodies were diluted in blocking buffer [5% bovine serum 
albumin (PAA, Germany), 10  mM Tris-HCl pH 7.4, 100  mM NaCl, 0.1% Tween® 20 (Merck)]. 
Protein bands were visualized using chemiluminescence detection kit, SuperSignal West Pico 
(Thermo Scientific, Rockford, USA) or SuperSignal West Femto (Thermo Scientific) according to the 
manufacturer’s instructions. Visualization of protein bands was done using a digital imaging system, 
SYNGENE G-Box, iChemXT. Protein expression was quantitated using Quantity One® software 
(Bio-Rad Laboratories, California, USA), normalized against actin levels. 
 
2.4. Immunoprecipitation and kinase assay 
Protein lysates were pre-cleared by incubating 1 mg of protein with sepharose beads (Protein 
A-Sepharose®; Zymed Laboratories Inc,, San Francisco; USA) for 30 minutes. Thereafter, protein 
lysates were incubated overnight with agitation at 4oC using 5 µg anti-Plk1 antibody (Life 
Technologies). Fresh sepharose beads were then added to the protein-antibody mixture and incubated 
at 4oC with agitation for another 3 hours for protein-antibody complex to bind to the beads. Sepharose 
beads were collected and washed 5 times with lysis buffer and finally, once with kinase assay buffer. 
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PLK1 kinase activity was determined using Z’LYTE™ Kinase Assay Kit (Life Technologies) that 
utilized Fluorescence Resonance Energy Transfer (FRET) between coumarin and fluorescein (FITC) 
of the peptide-based substrate. Reactions and quantitation were performed accordingly to 
manufacturer’s instruction. 
 
2.5. Flow cytometry analysis 
Neurospheres were dissociated with AccutaseTM (eBioscience), and blocked with FcR 
blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany). For stemness analysis, cells were 
stained according to manufacturers’ instructions with anti-CD133/2-allophycocyanin (Clone 293C, 
1:10 Miltenyi Biotec, #130-090-854), anti-CD15 (1:10, BD Biosciences, #347423), anti-Nestin (1: 
1000, Millipore, Massachusetts, USA, MAB5326). Aldehyde Dehydrogenase activity was determined 
using the AldeFluor™ kit (Stem Cell Technologies, Vancouver, Canada) according to manufacturer’s 
instructions. For ascertaining apoptosis, cells were stained with anti-cleaved-PARP (1:10, BD 
Biosciences, #552933). A total of 10,000 events were acquired on FACSCalibur instrument (BD 
Biosciences). Data were analysed using FlowJo software (Tree Star; Ashland, OR). 
 
2.6. Flow sorting of GPCs 
To isolate GPCs based on their CD133 status,  neurospheres were harvested and dissociated 
with AccutaseTM (eBioscience), and blocked with FcR blocking reagent (Miltenyi Biotec), and stained 
with anti-CD133/2-allophyocyanin (Clone 293C, 1:10 Miltenyi Biotec, #130-090-854) and 7-AAD 
viability dye (BD Pharmingen™) prior to cell sorting using BD FACSAria™ (BD Bioscience). For 








2.7. Tumor neurosphere assay 
For each GPC line, cells were sorted based on CD133 status using BD FACSAria™ (BD 
Bioscience). Thirty live cells were seeded per well in 96-well plate. Cells were sorted based on their 
CD133 status. Each well contained DMEM/F12 culture medium supplemented with growth factors. 
Cells were allowed to recover for 3-4 days, then treated with DMSO or BI2536 (Chemietek), and 
maintained until 21 days post-treatment at 37oC, in 5% CO2 humidified incubator. Drugs and growth 
factors were replenished twice a week. Neurosphere number and size were determined at day 7, 14 
and 21 respectively. A bona fide neurosphere is defined as a single sphere of diameter exceeding 20 
µm. Scoring and diameter measurements were performed using Nikon Eclipse Ti Microscopy, 
accompanied with digital camera (DS-Qi1) and NIS-Element Imaging Software (Nikon Instruments 
Inc., New York, USA).  
For evaluation of long-term BI2536 inhibition, 30 cells were seeded per well of 96-well plate 
with fresh media supplemented with only growth factors. Replenishment of growth factors was done 
twice weekly.  Neurosphere number and their size were determined at day 7, 14 and 21 post-drug 
removal.  
 
2.8. Cell cycle analysis 
Cells were harvested and fixed in cold 70% ethanol. Subsequently, cells were stained with 
cocktail consisting 4 µg/ml Propidium Iodide (Sigma-Aldrich) and 100 µg/ml RNase A (Sigma-
Aldrich). Data acquisition was performed using FACSCalibur instrument (BD Biosciences) and 
analysed using FlowJo software (Tree Star). 
 
2.9. Imunofluorescence analysis 
Neurospheres were dissociated enzymatically and seeded on laminin-coated (Sigma-Aldrich) 
8-well culture slides (BD Biosciences) at a density of 1.5 x 104 cells per well. Cells were fixed with 
4% paraformaldehyde (Sigma-Aldrich) for 10 minutes, permeabilized with 0.1% Triton X-100 
(Sigma-Aldrich) for 10 minutes, blocked with 5% FBS for 1 hour and stained for the following 
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markers: Nestin (1:300, Chemicon, MAB5326), Oct4 (1:100, Santa Cruz Biotechnology Inc., 
California, USA, H-134), Musashi-1 (1:100, Chemicon, AB5977), TuJ1 (1:200, Chemicon, 
MAB5326), GFAP (1:4000, Dako, Z0334), and oligodendrocyte marker (O4; 1:50, Chemicon, 
MAB345) . Secondary detection antibodies conjugated to Alexa-Fluor 488 or 594 (1:200, Molecular 
Probes, Life Technologies) were used. Finally, the culture slides were mounted with Vectashield® 
mounting media with DAPI (4,6-diamidino-2-phenylindole) (Vector Laboratories Inc., California, 
USA). Images were acquired with Olympus Fluoview 1000 confocal microscope (Olympus American 
Inc., Pennsylvania, USA). 
 
2.10. Differentiation of GPCs with BI2536 
GPCs were rescreened in a similar fashion as the initial high throughout screen. 
Concentrations that induced signs of differentiation in each GPC lines were determined and 
subsequent immunofluorescence analysis were performed using that concentration. GPCs were 
dissociated and seeded on laminin-coated (Sigma-Aldrich) 8-well culture slides (BD Biosciences) at a 
density of 1.5 x 104 cells per well. The media was removed and replaced with fresh media containing 
either DMSO or BI2536 at the concentration that induced differentiation. Fresh media with drugs 
were replaced every 4 days. At Day 10 post-treatment, cells were fixed with 4% paraformaldehyde 
and subjected to immunofluorescence analysis as described above. Scoring was performed using 
images captured on Nikon Eclipse Ti Microscope (Nikon Instruments Inc.). 
 
 
2.11. Lentiviral transduction 
PLK1 knockdown was achieved through pLKO.1-based vectors purchased from Open 
Biosystems (shPLK1 #1: TRCN0000006247; #2: TRCN0000121074, TurboGFP positive control 
vector: SHC003, Non-target shRNA control: SHC002). Viral particles were packaged using the Lenti-
X™ HTX Packaging System according to manufacturer’s instruction (Clontech). Virus titer of 
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supernatant collected was determined using Lenti-X™ p24 Rapid Titer Kit (Clontech) according to 
manufacturer’s instructions. 
PLK1 overexpression was achieved by utilizing pReceiver-mCherry or pReceiver-mCherry-
PLK1 lentiviral vectors (GeneCopoeia Inc., Maryland, USA). Viral particles were packaged using 
GeneCopoeia Lenti-Pac™ FIV Expression Packaging Systems (GenCopoeia Inc.) while virus titer 
was determined with Quicktiter™ Lentivirus Quantitation kit (Cell Biolabs Inc., San Diego, USA), 
according to manufacturer’s instruction. 
 
2.12. In vivo subcutaneous flank model of Balb/c nude mice 
Mice were handled according to the guidelines of the Institutional Animal Care and Use 
Committee, National Neuroscience Institute, Singapore. Approximately 2 million U87 glioma cells in 
200 µL of Phosphate Buffered Saline (PBS) were subcutaneously injected into the right flank of 6-8 
weeks old, female Balb/C nude mice (Animal Resource Center, Australia). Tumor dimensions were 
measured every 2 days using a vernier caliper, and the respective volumes were calculated using the 
following formula: Length x (Width2) x π/6. Mice were randomly put into 2 treatment groups; with 
saline control or BI2536 (Chemietek) treatment, at 50 mg/kg, 10 mL/kg body mass. BI2536 was 
reconstituted in 0.1N HCl diluted with 0.9% NaCl. Treatments were initiated when tumor volumes 
reached 0.5 cm3. For each treatment cycle, mice were given injections on 2 consecutive days per 
week. Maximum duration spanned 4 cycles from initiation of treatment. Tumor xenografts were 
harvested from mice at various cycles and paraffin wax-embedded for further analysis. 
 
2.13. Stereotaxic intracranial implantation of NOD-SCID gamma (NSG) mouse 
Animal experimentation was performed according to protocols approved by the Institutional 
Animal Care and Use Committee. Implantations were carried out as previously described99 using 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ NOD-SCID gamma mice (The Jackson Laboratory). The 
following coordinates were used: antero-posterior, +1.0 mm; medio-lateral, +2 mm; dorso-ventral, -
2.5 mm. Mice were euthanized by means of transcardiac perfusion with 4% paraformaldehyde upon 
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presentation of neurological deficits with ataxia, cachexia, lethargy or seizure. Hematoxylin-and-eosin 
(H&E) staining and immunohistochemistry were performed on 5 µm-thick paraffin sections. 
 
2.14. Karyotypic analysis of tumor neurospheres (conducted by Dr. SH Leong and A/Professor 
OL Kon, National Cancer Centre) 
Two million cells from dissociated neurospheres were cultured in T-25 flask (BD 
Biosciences). The cells were then treated within 3-5 days with 0.1 µg/ml colcemid (Life 
Technologies) for 24 hours. Metaphase-arrested cells were pelleted (180 g for 10 minutes) and treated 
with hypotonic solution of 0.075 M potassium chloride. Chromosomes were fixed in methanol:acetic 
acid (3:1) , re-centrifuged and resuspended in fixative. Twelve µl of the fixed cell suspension was 
dropped on a clean, moistened glass slide and placed on a hot plate at 48oC to obtain chromosome 
spreads. Spectral karyotyping (SkyPaint, Applied Spectral Imaging, Israel) was performed on 
metaphases according to the manufacturer’s instructions.  
 
2.15. Immunohistochemical staining of tumor tissues 
Both orthotopic and flank xenografts from mice were fixed in 4% paraformaldehyde, 
embedded in paraffin wax (Microm AP280-2, Zeiss), and sectioned (4 µm) using a microtome 
(Microm HM360, Zeiss). Hematoxylin and eosin (H&E) staining was performed as described in our 
previous work99. For antibody staining, we adapted protocols from Gritti et al.100. Briefly, sections 
were mounted on poly-L-lysine coated slides and subsequently processed for heat-induced epitote 
retrieval. Sections were blocked with 5% goat serum for 1 hour at room temperature and stained with 
Nestin (Chemicon, MAB5326) antibodies overnight, followed by incubation with HRP-conjugated 
secondary antibodies. Detection was performed using the ChemMate Detection Kit (Dako); a positive 
reaction was indicated by brown coloration using DAB (3,3’-Diaminobenzidine), and counterstained 





2.16. Microarray data acquisition of tumor neurospheres 
 For each sample, total RNA was isolated from neurosphere cells using TRI Reagent 
(Molecular Research Center, Cincinnati, OH). Thereafter, RNA samples were hybridized to 
Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array using 3' IVT express kit (Affymetrix 
Inc, Santa Clara, California). Data was deposited at private reviewer URL:  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=ztaxraywcqwkcbo&acc=GSE36782 
 
2.17. Bioinformatics analysis on public datasets (conducted by Edwin Sandanaraj, Singapore 
Institute for Clinical Sciences, A*STAR) 
Since brain tumors are driven by gene expression24, we sought to determine PLK1-associated 
pathway networks by tapping into 2 public glioma datasets, REMBRANDT101 and Gravendeel102. 
Raw cel files were downloaded from REMBRANDT application and gene expression omnibus (GEO) 
databases (GSE16011). The probe signals were processed using mas5 algorithm and non-exonic 
probes were removed. The probeset signals were consolidated to derive a unique gene-wise matrix as 
described in the genefilter package from R/bioconductor103. Briefly, the pre-processing approach 
restricted for probesets having entrez gene identifier and assigned the highest signaling probeset for 
the genes with multiple probesets. Pairwise interaction for the genes was measured using a rank-based 
correlation method. The PLK1 co-expressed genes were selected based on a cut-off coefficient (rs) of 
+/- 0.5. The same strategy was applied to both glioma datasets and the PLK1 co-expressed genes with 
consensus were selected as the PLK1 co-expressed gene module. The PLK1 co-expressed gene 
module was allowed to self-cluster among the glioma patients and the stratification pattern was 
dissected using cutree option in R. The self-clustered patient groups based on the PLK1 gene module 
were correlated for the survival pattern using the log-rank test. A Cox Regression model accounting 
for critical clinical covariates (age and histology) was built to assess the independent association of 





2.18. Pathway analysis (conducted by Edwin Sandanaraj, Singapore Institute for Clinical 
Sciences, A*STAR) 
 The biological relevance of the PLK1 co-expressed module was investigated by 2 different 
approaches. Metacore from GeneGo was explored to identify the significantly enriched biological 
pathways. Pathways with significant enrichment P-values of less than 0.05 were reported as 
significantly enriched networks. In addition, we used Gene Set Enrichment Analysis (GSEA) to test 
the gene module with the molecular signature database using GSEA tool downloaded from the Broad 
Institute portal104. We pre-selected 181 genesets related to stemness behaviour from the molecular 
signatures database (MSigDB)105. The PLK1 co-expressed gene module was tested for the enrichment 
with stemness signature gene sets. The significantly enriched associations were summarized as 
enrichment and the statistical scores were reported. A FDR cut-off of less than 25% was selected. 
 
2.19.  Quantitative real-time reverse transcription polymerase chain reaction 
 Extraction of RNA of NHA, NHNP and GPCs (NNI-1, 4, 5, 8 and 12) was performed using 
TRI Reagent® (Life Technologies) according to manufacturer’s instruction. Following on, 
approximately 5 µg of RNA was converted to cDNA using Superscript III First-Strand Synthesis 
System (Life Technologies). Subsequently, quantitative real-time reverse transcription polymerase 
chain reaction (qRT-PCR) was carried out using Power SYBR Green PCR Master Mix (Applied 
Biosystems, Life Technologies) together with a standardized amount of 25 ng cDNA for each sample.  
The cycle parameters on ABI 700HT (Applied Biosystems) were 40 cycles of 95oC  of 30 seconds, 
55oC at 30 seconds and 72oC at 30seconds. Each qRT-PCR was performed in triplicates and the 
expression of each gene was determined relative to the normalizer gene Hypoxanthine-guanine 







2.20. Mutational analysis of TP53 at codon 72 
 Genomic DNA from NHA, NHNP and GPCs (NNI-1, 2, 4, 5, 8, 11, 12 and 14) were extracted 
using DNeasy Blood and Tissue Kit (Qiagen, Duesseldorf, Germany).  The genetic variation in codon 
72 in exon 4 of the p53 gene was determined first by polymerase chain reaction (PCR) followed by 
BstU1 restriction enzyme digestion. Briefly, 100 ng of genomic DNA was used in PCR with 40 cycles 
of 95oC of 30 seconds, 58oC at 30 seconds and 72oC at 1 minute. Thereafter, PCR products were 
purified using QIAquick PCR purification kit (Qiagen) and subjected to 1 hour of BstU1 digestion at 
60oC. After digestion, DNA electrophoresis was done on 2% agarose gel for analyses.  
 
2.21. Statistical Analysis  
Data are expressed as means ± SD (standard deviation) or SEM (standard error of mean) of at 
least three independent experiments. Student’s t-test of the Mann-Whitney U test was used where 





CHAPTER 3: PLK1 AS A CANDIDATE REGULATOR OF GLIOMA-PROPAGATING 
CELL GROWTH 
 
3.1. GPCs phenocopy the primary tumor 
 Several works have previously shown that GPCs cultured as spherical structures in serum-free 
medium supplemented with growth factors contain phenotypic, transcriptomic and karyotypic profiles 
that mirror the patient’s original tumor11-12. Moreover, GPCs can be stably maintained by in vivo serial 
passage in immune-compromised mice2. However, it is unclear if GPCs contribute directly to disease 
progression and patient survival outcome. If so, it would be crucial to determine GPC regulatory 
pathways so as to design better therapeutics to effectively target the slow-growing but essential 
tumor-initiating and sustaining fraction. 
 In our study, we first verified our GPC collection according to our previous publication99. 
Essentially, we showed that GPCs re-establish orthotopic xenograft tumors that recapitulate the 
patient’s original histopathology, including the presentation of pseudopalisading cells interspersed 
with areas of necrosis and vascularization (Figure-4A). In addition, these cells contain karyotypic 
hallmarks commonly found in the original tumor, such as amplification of chromosome 7 (where 
epidermal growth factor receptor lies) and deletion of chromosome 10 (where PTEN lies) (Figure-
4B). Since large genomic efforts such as The Cancer Genome Atlas23 and REMBRANDT101 have 
demonstrated that brain tumors can be molecularly classified, we sought to characterize our GPCs 
molecularly by: (i) Relying on a previous GPC molecular classification scheme106, and (ii) 
Determining the subgroup of our GPCs together with other investigators’ GPCs. This approach would 
offer the advantage of profiling a larger and unique collection of GPCs with insight to their relation to 
the original primary tumor. Accordingly, we applied the molecular classification scheme in Lottaz et 
al.106 and assessed our GPCs with that of Gunther et al.107 and Pollard et al.108. Our data showed that 
our GPCs could be grouped into Proneural (NNI-1 to 5, 8, 12, 13) and Mesenchymal (NNI-9 to 11) 
classes (Figure-4C). The knowledge of such classes is important because they are enriched in distinct 
signaling pathways, thus targeting these pathways may offer therapeutic benefit by eradicating GBM 
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at its root. For example, Mesenchymal GPCs are typified by the TGF response pathway106,109, latter 
previously shown to maintain GPC survival and tumor-propagation110-111, and for which several TGF 
signaling inhibitors are in clinical trials112. Our findings validate our GPC collection. 
       




Figure-4. GPCs cultured in serum-free condition retain primary tumor phenotype. (A) Tumor 
xenografts phenocopied the patient’s original histopathology. Notably, (i) pseudopalisading cells 
interspersed with areas of (ii) vascularisation and (iii) necrosis were observed. (B) Cytogenetic analysis 
revealed retention of glioblastoma karyotypic hallmark; of note, amplification of chromosome 7 and 
loss of chromosome 10. (C) A 24-gene signature derived from Lottaz et al. classified our GPC 
collection (underlined with red), along with several other groups GPCs, into 2 molecular subtypes – 
Proneural and Mesenchymal. 
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3.2. Small molecule screen identifies inhibitors of GPC proliferation 
 To identify regulators of GPC survival, we adapted the screen design of Diamandis et al.113 
Briefly, to facilitate an initial, higher throughput screen of 50 small molecules targeting various 
oncologic pathways accessed from Eli Lilly pharmaceutical company, we carried out 2 steps: (i) We 
assayed for viability after 5 days of treatment with compounds at 10 M using 4 GPC lines (Figure-
5A). Compounds that reduced viability by more than 80% were subjected to, (ii) A second screen 
conducted at 0.1 M compound (Figure-5B). We then prioritized candidates that showed selectivity 
ratios > 2 in at least 1 GPC line (Table-2). The selectivity ratio represents % viability in normal mouse 
astrocytes (C8-D1A) / % viability in GPC; consequently a higher ratio reflects selectivity of GPC over 
normal astrocytic cells, latter of which characterizes the predominant cell type in glioma. Mouse 
astrocytes were utilized as fetal cells of human origin posed ethical issues for Eli Lilly. Notably, 3 
compound classes were identified that have already been implicated in GPC survival, thus validating 
our screening method; PI3K/AKT, GSK3, CDK1, 9 and TAK1 inhibitors114-115. Interestingly, a 
compound targeting PLK1 emerged, potentially identifying PLK1 as a novel regulator of GPC 
survival.  
 











Figure-5. High-throughput screen identifies GPC inhibitory compounds. GPCs (NNI-1, 4, 5 and8) 
and mouse astrocytes (C8-D1A) were subjected to drug treatment at (A) 10 µM and (B) 0.1 µM. 




Screen Compound No. Compound Target 
Viability Selectivity Ratio 
NNI-1 NNI-4 NNI-5 NNI-8 
I 
11 P70s8,PKAα,AKT 10.8 12.6 8.9 7.9 
14 GSK3β 3.5 1.2 1.7 7.2 
40 CDK1,9,TAK1 3.2 2.1 4.7 2.2 
II 
35 PLK1 - 1.2 - 2.0 
44 CDK9 - 2.5 - 3.7 
45 CDK9 - 1.7 - 1.9 
Table-2. List of prioritized compounds from high-throughput screen. Compounds were selected 
based on viability selectivity ratio (%ViabilityC8-D1A /  %ViabilityGPCs).  
35 
 
3.3. PLK1 mRNA expression is elevated in glioma tumors 
 PLK1 over-expression is common in several cancers of the breast116, ovaries117, prostate118 
and skin119. In addition, PLK1 protein expression has been documented to associate with higher 
glioma tumor grades86. We first verified PLK1 mRNA expression in 2 large, independent glioma 
clinical databases, REMBRANDT101 and Gravendeel102. We showed that PLK1 mRNA expression is 
elevated in gliomas, especially GBM, when compared to adjacent non-tumor tissue (Figure-6A). This 
verification is important as it sets the stage for addressing the clinical relevance of GPCs in primary 
tumors using gene expression. Next, we assessed PLK1 mRNA and protein expression in several GPC 
lines compared to normal human astrocytes (NHA) and normal human neural progenitor cells 
(NHNP). Our data indicated that PLK1 expression is likewise elevated in GPCs (Figure-6B), thus 
lending support to our hypothesis that PLK1 can present a viable therapeutic target via eradication of 
long-term, self-renewing GPCs. 
             
Figure-6. PLK1 is over-expressed in gliomas. (A) Expression of PLK1 is significantly higher in GBM  
compared to adjacent non-tumor tissue in glioma databases Gravendeel and REMBRANDT. ANOVA 
test was applied to compare the means of PLK1 expression from patients with different histological 
subtypes and non-tumor samples. (B) GPCs and ATCC glioma lines expressed higher levels of PLK1 
protein compared to non-tumor lines NHA and NHNP. U251, U87 and T98G represent commercially 
procured, serum-grown glioma cells (American Type Culture Collection). 
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CHAPTER 4: USING BI2536 TO STUDY PLK1 INHIBITION IN GLIOMA-PROPAGATING 
CELLS 
 
4.1. Verification of BI2536 efficacy in an in vitro kinase assay 
 PLK1 is a mitotic kinase which plays multiple roles in mitosis. PLK1 expression is cell cycle-
regulated, where its expression peaks at G2/M phase60. During G2/M transition, Aurora A and Bora 
work synergistically to activate PLK1 by phosphorylating Threonine 210 (Thr210) at its kinase 
domain63. Thereafter, PLK1 elicits a series of phosphorylation events leading to mitotic entry and 
eventually its own degradation mediated by the anaphase-promoting complex (APC)58. Several 
examples of downstream targets of PLK1 include cohesin120, BRCA276, CDC25C72, Cyclin B121 and 
kinesin-like motor protein122. The failure of PLK1 in phosphorylating these targets would thus lead to 
cell cycle defects. 
 To characterize PLK1 inhibition in GPCs, we relied on a well-published PLK1 small 
molecule inhibitor with known specificity that is currently in clinical trials for various oncologic 
diseases123, BI2536 (Supplementary Figure-1 and Supplementary Table-1). We first verified that our 
commercially procured BI2536 is comparable with published activity by determining its ability to 
inhibit phosphorylation of human recombinant PLK1 in a kinase assay. Our results showed that the 
inhibitory concentration which reduced phosphorylation by 50% was approximately 0.79 nM, which 











4.2. BI2536 selectively inhibits GPCs over normal human neural cells 
 Next, we determined the compound’s selectivity for GPCs over normal human neural cells by 
utilizing the selectivity ratio method as previously described113. We determined inhibitory 
concentrations which reduced viability by 50% (IC50) for each GPC, compared to NHA and NHNP 
cells (Supplementary Figure-S2). Collectively, we showed that BI2536 displayed a selectivity ratio of 
25 to 9621in GPCs compared to NHNP cells; while displaying a selectivity ratio of 1.4 to 560 when 
compared to NHA cells (Table-3). We rationalized that the significant differences between comparing 
to NHA and NHNP cells may lie in the fact that both are cultured under very distinct conditions: 
NHNP in serum-free medium supplemented with growth factors; and NHA in serum-containing 
medium. NHNP by virtue of being expanded under similar condition with GPCs may thus present a 
more reliable comparator cell. Taken together, we show that BI2536 acts selectively to inhibit GPCs. 
                              
 
                                                 
 
  
Figure-7. BI2536 treatment abrogates PLK1 kinase activity. (A) In vitro kinase activity of 
recombinant human PLK1 was markedly reduced with BI2536 treatment. An IC50 of approximately 
0.79 nM was derived. (B) PLK1 kinase activity expressed as % substrate phosphorylation versus 





4.3. BI2536 abolishes PLK1 kinase activity in GPCs and serum-grown glioma cells 
 We assessed kinase activity in patient-derived GPCs, as well as a panel of commercially 
available glioma cells namely U251MG, T98G and U87MG. In the experimental setup, cells treated 
with nocodazole were used as the positive control; reason being nocodazole arrests cells at G2/M 
phase124 and maximal PLK1 activity would be expected. DMSO was also included as the solvent 
control for unsynchronized cells. Upon BI2536 treatment, we observed that PLK1 kinase activity was 
markedly reduced in all cell lines when compared to nocodazole-treated and DMSO controls (Figure-
8). Notably, at least 70% reduction in kinase activity was recorded compared to the maximal activity 
in nocodazole-arrested cells. Our data illustrate that BI2536 effectively abolishes PLK1 activity in 
target cells. 
Cells IC50 (µM) 
IC50 Selectivity Ratio 
NHNP / GPC lines NHA / GPC lines 
NHA 3.399 - - 
NHNP 58.3600 - - 
NNI-1 1.2780 45.7 2.7 
NNI-4 0.0889 656.3 38.2 
NNI-5 1.8990 30.7 1.8 
NNI-8 0.0125 4672.5 272.2 
NNI-12 2.3690 24.6 1.4 
U251 0.0061 9594.7 558.8 
U87 0.1047 557.4 32.5 
T98G 0.0061 9620.8 560.3 
Table-3. IC50 concentrations and selectivity ratios of BI2536. BI2536 demonstrated at least 




              
 
          
 
 
4.4. BI2536 induces cell cycle effects in GPCs and serum-grown glioma cells 
 Next, we studied the effect of BI2536 on cell cycle profiles of GPCs and serum-grown glioma 
cells. We observed in serum-grown cells, an at least 2.5-fold increase in G2/M cells compared to 
DMSO-treated cells, consistent with the mechanism of BI2536; and an increase in sub-G0 cells at 48 
hours post-treatment, indicative of apoptosis (Figure-9). Similarly in GPCs, we noted an at least 2-
fold increase in G2/M cells compared to DMSO-treated cells (Figure-10). In addition, the sub-G0 cells 
increased steadily with time. In normal cells, p53-mediated apoptosis would be activated to remove 
effete polypoid cells; however, our glioma cells have been verified to possess mutated TP53 at codon 
72 (proline to arginine mutation)125 (Figure-11), thus explaining that BI2536 likely effected cellular 
apoptosis through p53-independent mechanisms. This is consistent with bioinformatical analysis in 
The Cancer Genome Atlas clinical database that revealed that PLK1 is frequently over-expressed in 
p53 mutant cells and are synthetically lethal126. We have further confirmed BI2536-induced apoptosis 
by flow cytometry using an antibody against cleaved poly[ADP-ribose] polymerase (PARP) (Figure-
12A). In addition, as flow cytometry allows for multiparameter monitoring in single cells, we assessed 
the levels of cleaved PARP in both CD133(+) and CD133(-) cellular fractions of GPCs (Figure-12B). 
Figure-8. BI2536 treatment abrogates PLK1 kinase activities of GPCs and glioma cell lines. In 
vitro kinase activities of GPCs and glioma cell lines were significantly reduced with BI2536 treatment.   
**p < 0.01, ***p < 0.001. 
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CD133 is frequently implicated as one of the GPC markers4, however, it should be noted that some 
gliomas can arise from CD133(-) cells27-28. Nevertheless, our data indicate that CD133(-) cells were 
more susceptible to BI2536-induced apoptosis when compared to CD133(+) cells across all GPC 
lines. This data may be explained in light of previous literature showing that CD133(+) cells have an 
activated DNA damage repair mechanism, possibly explaining for their survival advantage5,7. 
                 
 
 
Figure-9. BI2536 causes G2/M phase cell cycle arrest in glioma lines. (A) Representative FACS 
plots of BI2536-treated serum-grown glioma lines after 24h and 48h. (B) Bar charts representing 
averages of cell cycle FACS results (n=3). Notably, BI2536 induced G2/M phase cell cycle arrest 
with concomitant apoptosis as reflected by sub-G0 population. *p < 0.05, **p < 0.01, #p < 0.001. 
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Figure-10. BI2536 causes G2/M phase cell cycle arrest in GPCs. (A) Representative FACS plots of 
BI2536-treated GPCs after 24h and 72h. (B) Bar charts representing averages of cell cycle FACS results 
(n=3). Notably, BI2536 induced G2/M phase cell cycle arrest with concomitant apoptosis as reflected by 
sub-G0 population. *p < 0.05, **p < 0.01, #p < 0.001. 
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Figure-12. BI2536 induces apoptosis in GPCs and glioma cell lines. Expression of cleaved-PARP 
was assessed by flow cytometry. (A) Cleaved-PARP expression was elevated in glioma cell lines at 
24h and 48h post-treatment. (B) In GPCs, CD133(-) cells were more susceptible to BI2536-induced 
apoptosis in comparison to CD133(+). *p < 0.05, **p < 0.01. 
Figure-11. GPCs harbor TP53 mutation at codon 72. A single fragment of 880 bp after BstU1 
digestion indicates pro/pro expression of codon 72. Fragment sizes of 600 and 280 bp represent 
arg/arg while 880, 600 and 280 bp are arg/pro heterozygotes. 
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4.5. BI2536 abrogates clonogenicity of GPCs 
 Bearing in mind that GPC sphere cultures are heterogeneous, conventional short-term 
viability assays more than often produce erroneous results as they include readouts of majority cells 
such as the transient-amplifying progenitors55,127. True GPCs are slow-growing and the majority 
active cells mask their presence. We thus adapted the neurosphere assay which estimates bona fide 
tumor stem cell frequency, while sphere size indicates proliferative capacity113,128. This assay provides 
an in vitro readout of tumor stem cell activity that often correlates with survival outcome in orthotopic 
mouse models110,128. 
 We first determined sphere-forming ability of BI253-treated GPCs. To distinguish the effects 
in CD133(+) and CD133(-) subpopulations, we flow-sorted the cells and seeded at clonal densities to 
prevent cellular aggregation which leads to inaccuracy in determining bona fide spheres arising from 
stem cell self-renewal127. Based on the number of seeded cells in each well of a 96-well plate (n=30), 
we tabulated the percentage of neurospheres formed, as well as measured diameters of all spheres. In 
general, across all GPC lines used, we observed a decrease in sphere numbers in all 3 flow-sorted 
groups [total sorted, CD133(+) and CD133(-)] (Figure-13). Except for NNI-1, all other lines displayed 
at least 40% reduction in percentage of neurospheres formed at day 7 post-treatment. Subsequently, 
all cell lines displayed less than 20% sphere-forming activity by day 21. This data indicates that the 
tumor stem cell frequency was significantly reduced upon BI2536 treatment. Although we had 
previously shown that CD133(+) cells were more resistant to apoptosis by cleaved PARP analysis 
(Figure-12), the trend in the neurosphere assay was less clear. Sphere-forming ability in all total 
sorted, CD133(+) and CD133(-) fractions were similarly targeted. We also observed an increased 
percentage of smaller spheres in BI2536-treated GPCs regardless of their CD133 status (Figure-14). 
This is an indication of reduced proliferation or disintegration of the bigger spheres in response to 
BI2536 treatment. These data are not surprising considering that several other GPC markers besides 
CD133 have been shown to contribute to GPC survival and tumor propagation (e.g. CD15, nestin, 
aldehyde dehydrogenase [ALDH]26,29). While it is important to derive drugs that eradicate tumor-
initiating cells, other majority bulk tumor cells do play crucial roles in providing a suitable 
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microenvironmental niche that supports growth129. Thus, taken together, BI2536 shows efficacy at 
depleting the GPC frequency. 
 




Figure-13. BI2536 reduces tumor stem cell frequency. BI2536 treatment reduced neurosphere-
forming ability of GPCs. Notably, both CD133(+) and CD133(-) were equally targeted. *p < 0.05, **p < 





Figure-14. BI2536 reduces proliferation of GPCs. BI2536-treated GPCs showed an increased percentage of smaller spheres compared to 





4.6. PLK1 inhibition abrogates long-term self-renewal capability of GPCs 
 We expect that drugs truly effective against GPCs would not allow for recovery over a 
prolonged period. We therefore modified the neurosphere assay in which we withdrew BI2536 
treatment over 21 days, following the initial 14 days of drug treatment. This, we reasoned, would 
allow us to detect remnant self-renewal ability over the extended duration. To eliminate loss of 
tumorigenic potential due to cellular differentiation56, we replenished growth factors twice weekly to 
maintain GPCs in their relatively undifferentiated “stem” state.  
 We observed by day 7 post-drug withdrawal the following: A significant reduction in the 
number of spheres formed across all GPC lines (Figure-15) where there was at least a 70-90% 
reduction in number of spheres formed; by day 21 post-drug withdrawal, most BI2536-treated GPCs 
showed no signs of recovery as indicated by the progressive drop in sphere number and total 
eradication in NNI-8 and NNI-12; and sphere sizes indicating proliferative capacity were significantly 
reduced. Collectively, we show that BI2536 effectively abrogates bona fide long-term self-renewal 
ability of GPCs. 
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Figure-15. BI2536 effectively abrogates bona fide long-term self-renewal ability of GPCs. (A) 
Neurosphere-forming ability of GPCs remained minimal with drug withdrawal. (B) Distribution of 
neurosphere sizes showing smaller sphere sizes compared to DMSO-treated cells. In NNI-8 and NNI-
12, GPCs were totally depleted by Day 21. *p < 0.05, **p < 0.01, ***p < 0.001. 
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4.7. PLK1 inhibition alters GPC stemness expression 
 Recent findings provide insight into the role of cell fate in relation to tumorigenicity of 
GPCs56. Relatively undifferentiated tumor stem cells retain tumor-initiating and propagating activity 
while the more lineage-committed, differentiated progenitors exit mitosis and senesce, thus resulting 
in tumor involution56. Induction of differentiation in GPCs has thus been proposed as a viable 
therapeutic strategy. Accordingly, we sought to determine if BI2536 induced differentiation of GPCs. 
To-date, there is no single marker that clearly defines bona fide GPCs. Besides CD133, other genes 
commonly associated with stemness or self-renewal include CD15 (SSEA-1), nestin, SOX2, OCT-4 
and Musashi-1 (Msi-1)26,29,99. Such marker expression often generates conflicting data; moreover, 
their expression can be altered by experimental conditions130 and disease state131. Hence, we probed 
for a panel of 4 stemness-associated markers; namely CD133, CD15, ALDH and nestin, upon BI2536 
treatment. We observed that across all GPC lines, CD133 expression was reduced by at least 2-fold 
compared to DMSO-treated cells (Figure-16). Changes in CD15, ALDH and nestin expression were 
less obvious. In NNI-1 and NNI-5, CD15 expression doubled after BI2536 treatment. Taken together, 
these results suggest that PLK1 inhibition alters the GPC stemness profiles to varying extent. Our data 
underscores the limitation of relying solely on marker expression to characterize the GPC, thus 










4.8. BI2536 treatment induces cellular differentiation 
 To further substantiate our evaluation of BI2536 on stemness and differentiation profiles, we 
examined BI2536-treated GPCs at concentrations below their IC50 values to rule out non-specific drug 
effects (Table-4). We stained the cells with antibodies against nestin, Msi-1, Oct-4, glial fibrillary 
acidic protein (GFAP, astrocytes), -tubulin III (TuJ1, neurons) and O4 (oligodendrocytes)99. 
Preliminary analyses indicated that 4 out of 7 GPC cells displayed neurite outgrowth, indicative of 
differentiation (Figure-17). In general, all GPCs showed significant increases in differentiated cells 
although to varying extent with GFAP, TuJ1 or O4 (Figure-18). The stemness phenotype was not 
significantly altered, consistent with previous reports on tumorigenic GPCs exhibiting both 





Figure-16. PLK1 inhibition alters stemness profile of GPCs. Stemness profile of GPCs was 
assessed using a panel of stemness-associated markers, CD133, CD15, ALDH and Nestin. Across 5 





 Collectively, our data provides strong evidence that BI2536 targets GPCs via PLK1 
inhibition. This results in cell cycle arrest with concomitant apoptosis. Additionally, GPCs are 










                               
                                              
                                      
 
Table-4. BI2536 concentrations that induced GPC differentiation. 
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Figure-17. PLK1 inhibition by BI2536 induces cellular differentiation in GPCs. Neurite 
outgrowth (arrows), indicative of cellular differentiation were observed at lower concentrations 
of BI2536 treatments. Scale bar denotes 100 µm. 
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Figure-18. BI2536 induces differentiation of GPCs. (A) Four GPC lines showed increased 
expression of differentiation markers with BI2536 treatment. (B) Representative 
immunofluorescence images of NNI-4 subjected to DMSO or BI2536. (i) Co-staining of TuJ1, 
GFAP and DAPI, (ii) O4 with DAPI only. Nuclei were enlarged with BI2536 treatment. *p < 0.05, 
**p < 0.01, ***p < 0.001, scale bar denotes 10 µm. 
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CHAPTER 5: GENETIC KNOCKDOWN OF PLK1 MITIGATES GLIOMA CELL GROWTH 
 
5.1. GPCs are effectively transduced by lentiviruses 
 To rule out non-specific effects of BI2536, we performed lentiviral-mediated knockdown 
(shPLK1) to implicate PLK1 in maintaining GPC survival. Lentiviral transductions are efficient 
genetic manipulation tools. They infect both dividing and quiescent cells equally well, integrating into 
the host genome to sustain prolonged expression of the gene construct134. This makes them ideal for 
genetic manipulations in slowly-dividing stem-like GPCs. 
 Using the pLKO.1-puro-based vector (Figure-19), we performed PLK1 knockdown. To 
monitor transduction efficiency, we carried out, in parallel, transduction with clone SHC003, a 
TurboGFP-containing, non-targeting lentiviral vector of similar backbone as pLKO.1. This allows 
visualization of the green fluorescent protein which can be quantified by immunofluorescent methods. 
Figure-20 shows that by day 5 post-transduction, most GPCs expressed green fluorescence. Moreover, 
GFP expression was sustained till at least day 10, indicating that PLK1 knockdown was likely 
sustained. 
 
                                                    
 
Figure-19. Vector map of pLKO.1 lentiviral backbone. Vector is driven by the U6 promoter 










Figure-20. GPCs are effectively transduced by lentivirus. Successfully transduced GPCs were 
maintained in puromycin media for at least 10 days. Scale bar denotes 100 µm. 
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5.2. PLK1 knockdown levels are significantly reduced in GPCs and serum-grown glioma cells 
 We quantified the extent of PLK1 knockdown by immunoblot analysis (Figure-21). We 
observed a varying extent but consistent trend of reduced PLK1 protein across most glioma cells, 









Figure-21. PLK1 knockdown levels are significantly reduced in GPCs and glioma cell lines. 
(A)(i) Representative western blot analysis of glioma cell lines after shPLK1 knockdown. (ii) Bar 
chart representing averages of protein levels after shPLK1 knockdown. (B)(i) Representative western 
blot analysis of GPCs after shPLK1 knockdown. (ii) Bar chart representing averages of protein levels 
after shPLK1 knockdown. *p < 0.05, **p < 0.01, n=3. 
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5.3. PLK1 depletion reduces GPC viability and self-renewal capability  
 Next, we assessed the viability of glioma cells upon PLK1 knockdown at 2 time-points post-
transduction (Figure-22). We observed in both shPLK1 clones used that all glioma cell lines (patient-
derived as well as commercially procured, serum-grown cells) exhibited significant reduction in 
viability. Our data suggests that PLK1 regulates glioma cell proliferation. 
 











Figure-22. PLK1 depletion reduces GPC viability and self-renewal capability. (A) Viability of 
GPCs at Day 10 and 20 post-transduction. (B) Viability of glioma cell lines at Day 5 and 10 post-
transduction. *p < 0.05, ** p < 0.01. 
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5.4. PLK1 knockdown mitigates GPC clonogenicity 
We quantified the effects of PLK1 knockdown on sphere-forming capacity, an indicator of 
GPC frequency and self-renewal. Our results showed that over an extended period of 21 days post-
transduction, sphere formation was greatly reduced, with concomitant reduction in sphere size, latter 
being an indicator of GPC proliferation (Figure-23). These data support our hypothesis that PLK1 is a 
viable molecular target at eradicating self-renewing GPCs. 
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Figure-23. PLK1 knockdown mitigates GPC clonogenicity. Both shPLK1 clones reduced self-
renewal ability of GPCs effectively. (A) PLK1 depletion reduced tumor stem cell frequency of GPCs 
as depicted by a decrease in percentage neurospheres formed. (B) Distribution of neurosphere sizes for 
each GPC line. Smaller spheres were more prominent in shPLK1 knocked down samples compared to 
their respective controls. In NNI-8, GPCs were totally depleted by Day 14. *p < 0.05, **p < 0.01. 
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5.5. PLK1 knockdown has moderate effects on stemness and differentiation profiles 
We next examined PLK1 knockdown on the stemness and differentiation profiles of GPCs. 
We assessed the levels of CD133, CD15, ALDH and nestin (stemness markers); and TuJ1, GFAP 
(differentiation markers) at day 5 post-transduction. Figure-24 demonstrates that no major changes in 
stemness expression were observed. Contrary to our earlier BI2536 data, we could not detect signs of 
differentiation. We verified this by immunoblot analysis of GFAP and TuJ1 expression (Figure-25). 
Collectively, our data suggests that PLK1 depletion effects cell death by apoptosis, and may have 
moderate roles in determining cell fate. Our genetically acquired data differed from BI2536 data with 
respect to stemness and differentiation profiles, likely due to the non-specific action of BI2536. 






Figure-24. PLK1 knockdown has moderate effects on stemness profiles of GPCs. No significant 














Figure-25. Western blot analysis demonstrates reduction of differentiation markers with PLK1 
knockdown. Differentiation markers GFAP and TuJ1 were probed in western blot analysis. (A) 
Representative western blots of shPLK1 GPC lines. (B) Bar charts representing average expression of 
(i) GFAP and (ii) TuJ1, (n=2). GFAP protein was undetectable in NNI-1, 5 and 12. 
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5.6. PLK1 over-expression rescues BI2536 inhibition 
 To gain insight into the molecular mechanism behind BI2536 inhibition of glioma cell 
growth, we proceeded to over-express PLK1 in a lentiviral vector, and then determine its ability to 
rescue growth inhibition in transduced cells upon BI2536 treatment. This approach would definitively 
implicate PLK1 in BI2536 inhibition mechanism and support that previous in vitro observations are 
most likely attributed to specifically PLK1 inhibition. 
 Accordingly, we lentivirally transduced GPCs with either vector control or PLK1-over-
expressing vector, both bearing mCherry as a visualization marker for assessing transduction 
efficiency (Figure-26). Lentiviral transduction was previously demonstrated to be an effective genetic 
manipulation tool in slow-growing, non-dividing stem-like cells128. We then treated the cells with 
BI2536 and determined cell viability after 3 days. First, we observed that despite using similar 
multiplicity of infection (MOI), GPC lines varied in transduction efficiencies for both vectors, further 
confirmed by FACS analysis (Figure-27). This is likely due to individual patient line variations 
typically seen in studies involving clinical specimens110-111. In addition, PLK1 over-expression is 
known to cause cellular transformation96 and may thus affect the perpetuation of PLK1-over-
expressing clones. Secondly, since transduction efficiencies differed and may confound data 
interpretation, we flow-sorted and analyzed equal numbers of mCherry-positive cells from both 
control and PLK1-over-expressed cells. Immunoblot analysis confirmed the over-expression of PLK1 
(Figure-28). Our data showed that across all GPC lines tested, PLK1 over-expression was sufficient to 
nearly fully rescue BI2536 inhibitory effects on cell proliferation (Figure-29). 
 
Summary 
Our data provides evidence that PLK1 inhibition accounts for the inhibitory effect of BI2536 













Figure-26. Vector map of pReceiver lentiviral backbone. Vector is driven by CMV promoter, 
contains mCherry fluorescence marker for visual tracking and puromycin selectable marker for 
establishment of stable clones.  
Figure-27. Transduction efficiency varies among GPC lines with pReceiver lentiviral 
backbone. Representative FACS plots of GPCs transduced with mCherry or mCherry-PLK1 




                 
 









Figure-28. PLK1 is over-expressed in lentivirally transduced GPCs. Representative western blots 
of GPCs transduced with mCherry or mCherry-PLK1 constructs.  
Figure-29. PLK1 over-expression rescues BI2536 inhibition. PLK1 over-expression resulted in 
near complete rescue of cell viability after BI2536 treatment. *p < 0.05, **p < 0.01, ***p < 0.001. 
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CHAPTER 6: BI2536 TREATMENT MITIGATES GLIOMA GROWTH IN MOUSE 
XENOGRAFT MODEL 
 
6.1. BI2536 treatment mitigates glioma growth 
Due to the reproducibility and experimentally feasible, short-term latency of U87MG glioma 
cells, together with the finding that they possess a tumor-initiating and sustaining GPC-like 
fraction135, we decided to evaluate the effects of BI2536 in subcutaneous xenografts of BALB/c nude 
mice, a system which allows for relative ease in monitoring tumor volume changes. The efficacy of 
PLK1 small molecule inhibitors including BI2536 have already been demonstrated in several other 
tumor systems123,136-138. 
 Accordingly, we implanted U87MG cells into the flanks of nude mice and monitored tumor 
volume and weight of mouse. When tumors reached 0.5 cm3, we subjected the mice to either vehicle 
control or BI2536 intravenous tail-vein injections123. Tumor volume was measured every 2 days until 
termination of experiment where maximal tumor size was humanely possible. By 2 cycles of 
treatment, BI2536-treated animals exhibited reduced tumor volumes although not significant (Figure-
30). By 3 cycles of treatment, BI2536-treated animals displayed significantly reduced tumor volumes 
by more than 2-fold compared to vehicle-treated animals (BI2536, n=16; vehicle, n=8); however, no 
significant difference was observed when compared to the initial tumor size at 0 cycle. Also, the 
average body weight of mice was reduced by approximately 10%, suggesting that BI2536 was 
tolerated with minimal toxicity. Our data provides evidence that BI2536 mitigates glioma growth via 









          
 
  Figure-30. BI2536 treatment mitigates glioma growth. Photographs of control and BI2536-treated 
mice after (A) 2 cycles and (B) 3 cycles of treatment. (C) Average tumor volume of BI2536-treated 
mice was significantly smaller than control-treated after 3 cycles of treatment. Reduced rate of tumor 
growth indicated cytostatic effects of BI2536 treatment. *p < 0.05, ***p < 0.001. 
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6.2. BI2536 induces apoptosis 
 Next, we analyzed the mouse tumors by immunohistochemistry using the Terminal 
deoxynucleotidyl transferase dUTP nick End Labeling (TUNEL) assay that detects cell death by 
apoptosis. Consistent with the role of PLK1 inhibitors at inducing mitotic arrest with concomitant 
apoptosis123,136-138, we observed that BI2536-treated tumors displayed significantly increased number 
of TUNEL-positive cells (Figure-31). These data suggest that BI2536 induces cell death by apoptosis, 
likely a contributing factor to the reduced tumor volumes. 




Figure-31. BI2536 induces apoptosis. BI2536-treated mice presented higher percentage of 
TUNEL+ cells, indicative of apoptosis. *p < 0.05, scale bar denotes 50 µm. 
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6.3. BI2536 targets Nestin-expressing glioma cells 
 One of the most important findings of our in vitro experiments points to the specific targeting 
of GPCs via the PLK1 signaling mechanism. Although most standard animal oncology models utilize 
tumor volume changes or survival as endpoints for determining the efficacy of treatments, these 
measures do not reveal the changes within GPCs, typically forming the minority cellular fraction but 
crucial for tumor-initiating and sustaining activity. In other words, tested treatments may inhibit 
majority, fast-growing cells but miss targeting the essential slow-growing, tumor-propagating 
fraction. The cancer stem cell hypothesis forces a re-evaluation of such endpoints for measuring 
inhibition of GPCs132. Accordingly, we determined the number of Nestin-positive cells in our tumor 
xenografts. Nestin frequently marks early neural precursors139 and has been shown to be vital for 
glioma-propagating activity26. We observed that BI2536-treated tumors displayed significantly 
reduced but moderate number of Nestin-positive cells compared to vehicle-treated tumors by the third 
cycle of treatment (Figure-32). CD133 was not analyzed in the immunohistochemical sections due to 
inconsistencies arising from the choice of antibody clones used140. Our data suggests that BI2536 
targets Nestin-expressing neural precursors. 
        
 












 Our animal model illustrates a cytostatic effect of BI2536 via apoptosis, and that Nestin-
expressing GPCs are targeted. Although our data are moderately significant, nonetheless, they imply 
that combinational therapy to inhibit both self-renewing GPCs and bulk tumor cells may present a 
more effective therapeutic approach. 
Figure-32. BI2536 targets Nestin-expressing glioma cells. BI2536-treated mice presented 
marginally lower percentage of Nestin-positive cells. **p < 0.01, scale bar denotes 50µm. 
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CHAPTER 7: PLK1-HIGH GENE SIGNATURE PORTENDS POOR PROGNOSIS 
(Conducted by Edwin Sandanaraj, Singapore Institute for Clinical Sciences, A*STAR) 
As our in vitro observations and animal model by no means represent perfect recapitulations 
of the tumorigenic process, we sought to analyze PLK1 pathway relevance in patient clinical 
databases to substantiate our hypothesis. Our earlier data demonstrated that high PLK1 mRNA 
expression in glioma patients (Figure- 6). Others have similarly observed that high PLK1 protein 
expression is present in higher tumor grades of clinical specimens, correlating with poorer survival86. 
Although the role of PLK1 in brain tumors is not new, we emphasize that our approach seeks to 
establish the direct link between patient-derived GPCs and disease progression and survival outcome. 
This is an important endeavor for the following reasons: (i) GPCs are controversial cells as their cell-
of-origin in clinical specimens cannot be identified. Consequently, their clinical relevance and utility 
are questionable. Our effort will show that these cells contribute molecularly to patient survival 
outcome; (ii) We will show that brain tumors are molecularly heterogeneous and that the PLK1-high 
gene signature functions as an independent negative prognostic factor in brain tumors, considering 
current clinical indicators such as age and histology; and importantly, (iii) Our work will highlight the 
limitations of relying solely on morphology-based histological methods to diagnose and subsequently 
treat patients. 
 
7.1. A PLK1 gene signature is generated  
Accordingly, we utilized 2 of the largest brain tumor clinical databases, REMBRANDT101 
(N=298) and Gravendeel102 (N=276), to generate a “PLK1 gene signature”. In this process, we looked 
for genes that are significantly co-expressed with PLK1 mRNA expression (Supplementary Table 2, 
correlation coefficient of  ±0.5). We generated a list of 175 genes which intersected the 2 databases, 
of which, 171 genes that are positively correlated to PLK1 expression and 4 inversely correlated. 
Collectively, these 175 genes represent our PLK1 gene signature. A pathway network analysis on 
PLK1 gene signature using GeneGo revealed that mainly cell cycle signaling modules are enriched 









Figure-33. GeneGo pathway network associated with PLK1 gene signature. Genes associated 
with high and low PLK1 expression are mainly cell cycle-related networks. 
72 
 
7.2. PLK1 gene signature stratifies brain tumor patient survival 
Next, we asked if patient survival varied between the PLK1-high and –low groups. We 
performed self-clustering of the PLK1 gene signature and observed that it significantly stratified 
patients’ survival (REMBRANDT, p=2e-06; Gravendeel, p=1e-10) (Figure-34). Poorly surviving 
patients were enriched in the PLK1-high gene signature while patients with better prognosis tended to 
fall into the PLK1-low group. Furthermore, multivariate analysis indicated that the PLK1 gene 
signature predicted survival independently of age and histology (Table-5; REMBRANDT, p=7.11e-
05; Gravendeel, marginal insignificance, p=0.0721), suggesting that the gene signature defines 
molecular heterogeneity in the tumors that cannot be accounted for by current clinical indicators. 
As several efforts have shown that gene expression drives molecular subgrouping of brain 
tumors24,102,141-142, furthermore with each subgroup showing unique genomic, karyotypic and clinical 
profiles, we sought to examine closer the PLK1-high and –low expression patient tumors. We 
observed that PLK1-high tumors tended to exhibit Mesenchymal features of higher grades, typified by 
highly aggressive and recurrent tumors142 (Figure-34). In contrast, PLK1-low tumors displayed 
Proneural molecular features, consistent with lower tumor grades142. The ability to draw connections 
between the PLK1-stratified patient groups and tumor molecular features is an important advance as it 
allows us to study primary tumor features that cannot be predicted by age and histology alone. This 
has significant implications as now, no 2 patient tumors are viewed alike based on molecular features, 
even though their histologies may be identical. This molecular heterogeneity may thus account for the 
frequently observed inter-patient variability to treatment response. 
To further substantiate that GPC-like properties may account for PLK1-high and –low 
primary tumor behavior, we used Gene Set Enrichment Analysis143 to determine if core stem cell 
programs can be enriched in the PLK1-stratified tumors. The core stem cell programs include 
signatures derived from embryonic, hematopoietic and neural stem cells and were utilized in a 
previous cancer stem cell-based approach by Nevins and colleagues32. This is a reasonable approach 
for us as both embryonic and neural stem cell modules have previously been shown to modulate brain 
tumor progression128. Accordingly, we observed that the PLK1-high patient tumors are enriched in 
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key stem cell modules signaling extensive self-renewal and proliferation (Supplementary Table-3). 
Interestingly, both Nanog128 and Myc144 were previously implicated as regulators of GPC sustenance. 
To verify that our bioinformatical predictions about PLK1-associated genes are valid in GPCs, we 
first filtered out neural stem cell modules and then investigated the expression of several well-known 
cell cycle-related genes which have been implicated in tumorigenesis. They include NIMA (never in 
mitosis gene-a)-related kinase 2 (NEK2), DNA topoisomerase 2-alpha, (TOP2A), protein regulator of 
cytokinesis 1 (PRC1), Epithelial Cell Transforming Sequence 2 (ECT2) and Forkhead box protein M1 
(FOXM1). Our data consistently showed up-regulation of these genes in GPCs as compared to NHA 
cells (Figure-35). These data suggest that our GPCs represent biologically relevant cellular models of 
PLK1-over-expressed tumorigenic cells. 
  Collectively, our data provide strong evidence that stem cell-like traits are important in 
conferring the PLK1-high primary tumor phenotype, and consequently poor patient survival.               
 
Summary 
Our data provides strong evidence for the role of GPC-like traits in conferring the poor 
prognosis outcome of PLK1-high patients. These traits comprise extensive self-renewal and 
proliferating capabilities. In addition, our PLK1 gene signature highlights the molecular heterogeneity 
of brain tumors that cannot be accounted for by current clinical indicators, age and histology. This 
finding forces a re-evaluation of the use of morphology-based pathological analyses to diagnose and 












Figure-34. PLK1 gene signature stratifies patient survival. From glioma databases (A) 
Gravendeel (B) REMBRANDT, PLK1-high group portends poorer survival and comprises the 
more aggressive tumor subtypes, namely Proliferative and Mesenchymal. Kaplan-Meier plots were 
drawn to show the cumulative probability of survival over the time from PLK1 subgroups. A log-
rank test p-value was computed to determine the significant difference between PLK1 subgroups. 
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Figure-35. Quantitative real-time qRT-PCR analysis demonstrates up-regulation of cell 
cycle-related gene in GPCs. Cell cycle-related genes NEK2, TOP2A, PRC1, ECT2 and FOXM1 




Table-5. Multivariate Cox regression analysis of PLK1 gene signature with age and histology. 
Gravendeel     
Covariates Exp (coeffient) 
Std 
error 95% CI p-value 
PLK1 Signature PLK1 Low 0.4676 0.1914 [0.3214-0.6804] 7.11E-05 
Histology GBM  1.1131 0.2452 [0.6884-1.7997] 0.6621 
Histology MIXED 0.2807 0.2986 [0.2807-0.9051] 0.0218 
Histology OLIGODENDROGLIOMA 0.3042 0.2767 [0.1769- 0.5232] 1.70E-05 
Age 1.0432 0.00554 [1.0319-1.0546] 2.36E-14 
 
     
REMBRANDT     
Covariates Exp (coeffient) 
Std 
error 95% CI p-value 
PLK1 Signature PLK1 Low 0.7694 0.1458 [0.5782-1.024]  0.0721 
Histology GBM  2.4566 0.1832 [1.7156-3.518]  9.27E-07 
Histology MIXED 0.9702 0.4694 [0.3866-2.435]  0.9487 
Histology OLIGODENDROGLIOMA 0.9468 0.2448 [0.5860-1.530]  0.8233 
Age 1.0129 0.0047 [1.0036-1.022]  0.0063 
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CHAPTER 8 – GENERAL DISCUSSION 
 One of the central tenets in cancer stem cell biology is understanding the cellular 
heterogeneity of tumors, and consequently what impact it has on experimental designs. Traditional 
short-term viability assays are fast methods in high-throughput screens; however, they often do not 
reflect effects on bona fide self-renewing cells in a surrounding of transient-amplifying progenitors. 
Thus, small molecule screens based on cancer stem cells must take into account the need to 
incorporate assays that measure long-term self-renewal in slow-growing cells. This is an important 
concept as small molecule candidates may, through viability assay prioritization, eradicate bulk 
tumors without inhibiting the most essential, tumor-initiating and sustaining fraction. Consequently, 
tumor recurrence is inevitable. To design better therapeutic strategies against these highly infiltrative 
and recurrent gliomas, the targeting of GPCs is essential. Here, we show that the well-developed 
neurosphere assay in neural stem cell biology provides a reliable method to assay for self-renewal145; 
in addition when combined with serial transplantation in mice, tumor-initiating and sustaining activity 
is measured. The prioritization of small molecule candidates based on the selectivity ratio enables 
GPC-specific targeting to be delineated from toxicity to normal cells.  
In vivo efficacy of BI2536 in reducing tumor cell proliferation has been demonstrated by 
several groups90,123,146-148. We therefore tested the efficacy of BI2536 in Balb/C nude mice engrafted 
with U87MG serum-grown glioma cells, previously shown to contain a stem-like population 
responsible for tumor initiation135. Our results showed cytostatic effects on glioma growth. 
Conceivably, differences in experimental parameters such as choice of cell lines and onset of 
treatment might have contributed to the moderate effects. Also, further in vivo assessment of 
pharmacodynamics is desired as it will shed light on BI2536 levels within the tumor and animal body. 
Nonetheless, BI2536 has already shown promising results in clinical studies, together with various 
PLK1 inhibitors such as BI6727, ON01910 and GSK461364149-152. Furthermore, these compounds 
have shown favorable toxicity profiles in patients receiving the treatment.  
We have seen that bioinformatics analyses revealed higher PLK1 expression in GBM tissue 
compared to normal brain, thus validating our initial screen design on selectivity ratios to prioritize 
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compounds. While preparing this thesis and manuscript, an article was published on the novel role of 
PLK1 in regulating survival of GBM GPCs, thus validating our approach and conclusions90. Our work 
extends upon their findings by querying the contribution of GPCs to patient survival outcome, thus 
providing a direct relationship between these cells and the primary tumor phenotype; consequently 
validating their use as an in vitro cellular screening system tailored towards stem cell-specific 
parameters. Admittedly, such extended and in-depth sphere assays would not be amenable to high 
throughput screening in the traditional sense (i.e. thousands of compounds) but we wish to emphasize 
a re-evaluation of screening criteria to detect long-term self-renewing GPCs. 
Cancer stem cells are controversial cells mainly because they have been shown to initiate 
tumors in mice at varying frequencies depending on tumor subtype and experimental conditions, 
indicating that the tumor-initiating capacity, a central theme in cancer stem cells, may actually be an 
artefactual consequence of experimental parameters27,130. This forces a re-definition of cancer stem 
cells to focus on the most important criteria: Long-term self-renewal and the ability to recapitulate the 
primary tumor pathophysiology. Still, the question remains as to whether such cells are clinically 
meaningful if they constitute an often small fraction of the tumor mass. Here, we have tapped into 
large, public glioma databases to evaluate the prognostic value of PLK1 gene expression. Although 
our conclusions are not entirely novel in that previous works have indeed implicated high PLK1 in 
GBM specimens and cell lines86; moreover PLK1 is synthetically lethal with TP53 mutation in 
GBM126, we show that genes associated with PLK1 high patient cohort encompass several stem cell-
like candidates, several of which contribute to clinical outcome in other cancers31-32,153. Noteworthy, 
our PLK1 high expression is enriched for the Proliferative and Mesenchymal molecular subclasses in 
glioma databases comprising various tumor grades and histologies. Such findings imply that the 
choice of patient databases/histologies and conceivably molecular heterogeneity of primary tumors 
affect the assignment of PLK1 high and low groups. Furthermore, it shows that although the PLK1 
gene signature has a prognostic role, its true predictive value would have to be determined using a 
prospectively collected patient cohort subjected to PLK1 inhibition therapy.  
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These data collectively highlight the value of GPCs in determining disease progression and 
patient outcome, and that by inference; their targeting should present a long-lasting, effective cure. 
The additional understanding that PLK1 targeting occurs at the level of GPCs should therefore 
prioritize the development of this class of compounds in glioma therapy. Our findings also suggest 
that PLK1 expression predicts molecular heterogeneity that cannot be accounted for by histology 
alone. This highlights the limitation of morphology-based approaches in patient diagnosis and 
consequently impacting on treatment decision. Our work further supports that patients with elevated 
PLK1 signaling pathway may thus be amenable to PLK1 inhibition therapies. In summary, we show 
the relevance of GPCs as a valuable in vitro screening platform, and further validate their prognostic 
significance in disease progression and patient survival outcome. 
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8.1. Future directions 
Our work sheds light on the role of PLK1 in mitigating GPC survival, and importantly, in 
tumor growth in a nude mouse model. Ideally, we would like to conduct BI2536 dose efficacy studies 
using orthotopic mouse models of glioma established from patient-derived GPCs, and treating the 
animals by oral gavage to simulate actual patient scenarios. The feasibility of this approach has 
recently been demonstrated in glioma biology90. 
In addition, we would like to explore deeper the mechanism behind PLK1 inhibition. 
Conceivably, we could subject GPCs transduced with non-targeting and shPLK1 lentiviral clones to 
genome-wide gene expression analysis. We could then define a differential gene list, and interrogate 
its pattern of association in patient gene expression data. We showed recently that the Connectivity 
Map offers a technically feasible method to carry out this gene association study13,154-155. Such a 
method has several advantages: (i) It allows data from various platforms to be integrated and analyzed 
in association with each other through the common language of gene expression, previously shown to 
drive glioma disease progression; (ii) it allows us to determine patient cohorts likely to receive 
treatment benefit through PLK1 inhibition; and (iii) it allows us to identify patient genetic 
characteristics associated with a favorable response, as these patient databases contain deep 
sequencing information. Such an endeavor would enable us to draw a connection between our in vitro 
PLK1 inhibition-induced tumor cell death, and patient treatment profiles. Our work will redefine the 
utility of molecularly driven, genome-informed decisions in tailoring therapies for glioma patients. 
Finally, we recently showed that GPCs from major glioma variants phenocopy their original 
patient’s biological and transcriptomic programs, and contributed to different signaling pathway 
activation in patient cohorts13. This work has significant implications as it means we can now tap into 
our patient-derived GPCs to establish orthotopic xenograft tumors for preclinical drug testing. Our 
GPCs thus represent patient-mouse tumor replicas that can be prospectively mined for drug responses, 




GPCs are clinically relevant tools which reflect the biology and transcriptomic programs of 
the patient’s original primary tumor. We provide evidence that PLK1 is a viable therapeutic target and 
its inhibition abrogates glioma growth. Our bioinformatical analysis highlights that the PLK1 high 
signature is a negative prognostic factor; furthermore, correlates with highly aggressive, infiltrative 
and recurrent tumors. Our work highlights the limitation of relying solely on morphology-based 
histological methods to diagnose and subsequently treat patients. Gliomas are thus viewed as 
molecularly heterogeneous cancers24,102,142,156. With the advances of public efforts in gathering deep 
sequencing information of patient primary tumors23,101, glioma biology is now well-poised to 
interrogate the feasibility of genome-informed treatment strategies. Our study here provides the first 
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Figure-S1: Chemical structure of BI2536.  
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Figure-S2: BI2536 IC50 kill curve in GPCs and ATCC glioma cell lines.  
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Supplementary Table-1. BI2536 kinase selectivity profile 
Kinase   IC50 (μM)   Kinase  
IC50 
(μM)   Kinase   
IC50 
(μM) 
Plk1* 0.013 Erk2 >20 Nik* >20 
Plk2* 0.019 Fgfr1 >20 Nlk >20 
Plk3* 0.016 Fgfr2 >20 p38a >20 
Plk4* >20 Fgfr3 >20 p38b >20 
Abl >20 Fgfr4 >20 p38d >20 
Akt1 >20 Flt1 >20 p70s6 >20 
Akt2 >20 Flt3 >20 Pak2 >20 
Akt3 >20 Flt4 >20 Pak3 >20 
Alk* 3.700 Fms >20 Pak5 >20 
Alk4 >20 Gsk3a >20 Pask >20 
Ask >20 Gsk3b >20 Pdgfra >20 
AurA >20 Hipk2 >20 Pdgfrb >20 
AurB >20 Ikka >20 Pdk1 >20 
Brk >20 Ikkb >20 Pim1 >20 
Brsk >20 Ikke* >20 Pim2 >20 
Camk1 >20 InsR >20 Pkaa >20 
Camk2a* 3.750 Irak1 >20 Pkca >20 
Camk4 >20 Irr >20 Pkcb >20 
Cdc7 >20 Jak2 >20 Pkca >20 
Cdk1/cycB >20 Jak3 >20 Pkcb1 >20 
Cdk2/cycE >20 Jnk1 >20 Pkcb2 >20 
Cdk3/cycE >20 Jnk2 >20 Pkc eta >20 
Cdk4/cycD1* 7.830 Kit >20 Pkc t >20 
Cdk5/p35 >20 Limk1 >20 Pkc z >20 
Cdk6/cycD3 >20 Lkb1 >20 Pkg1b >20 
Cdk7/cycH/MAT >20 Lok >20 Raf >20 
Cdk8* >20 Lrrk2* >20 Ripk2 >20 
Chk1 >20 Mark1 >20 Rock1 >20 
Ck2 >20 Mek1 >20 Rock2 >20 
Csk >20 Met >20 Ron >20 
Dapk1 >20 Mink1 >20 Ros >20 
Ddr2 >20 Mk2 >20 Rse >20 
Dmpk >20 Mk3 >20 Sgk >20 
Drak1 >20 Mk5 >20 Sgk3 >20 
Dyrk2 >20 Mkk6 >20 Sik >20 
Eef2k >20 Mlk1 >20 Src >20 
EphA3 >20 Mlk2* >20 Srpk1 >20 
EphA5 >20 Mnk2 >20 Tak1 >20 
EphA7 >20 Mst1 >20 Tie2 >20 
EphB1 >20 Mst2 >20 TrkB >20 
EphB2 >20 mTor >20 Ulk1* >20 
EphB3 >20 Musk >20 VEGFR2 >20 
EphB4 >20 Nek6 >20 Wnk3 >20 
ErbB4 >20 Nek7 >20 Zap70 >20 




   Supplementary Table-2. Genes associated PLK1 expression  




















factor 1, subunit A (p150) 
[Source:HGNC 
Symbol;Acc:1910] 
8.0338 6.7268 1.3070 4.66E-27 8.1335 7.2393 0.8941 1.92E-17 
SMC4 10051 




10.9876 9.2451 1.7425 1.71E-61 11.4750 9.7853 1.6897 7.19E-42 
KIF20A 10112 
kinesin family member 
20A [Source:HGNC 
Symbol;Acc:9787] 
8.9651 5.7365 3.2286 1.70E-63 8.7840 6.3825 2.4016 1.30E-61 
CDK2 1017 
cyclin-dependent kinase 2 
[Source:HGNC 
Symbol;Acc:1771] 
10.2607 9.0639 1.1968 1.35E-52 9.0890 7.9091 1.1798 8.10E-27 
CDK4 1019 
cyclin-dependent kinase 4 
[Source:HGNC 
Symbol;Acc:1773] 
12.1169 11.0676 1.0493 8.72E-17 12.1518 11.3260 0.8258 7.61E-10 
DDX39A 10212 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
39A [Source:HGNC 
Symbol;Acc:17821] 










component (S. cerevisiae) 
[Source:HGNC 






MAD2 mitotic arrest 
deficient-like 2 (yeast) 
[Source:HGNC 
Symbol;Acc:6764] 




protein 3 [Source:HGNC 
Symbol;Acc:11524] 
8.6514 5.4576 3.1938 1.13E-71 8.6616 6.7097 1.9519 1.73E-43 
CENPA 1058 
centromere protein A 
[Source:HGNC 
Symbol;Acc:1851] 
8.7886 6.7708 2.0178 2.17E-68 9.0543 6.5865 2.4678 2.34E-56 
SMC2 10592 




9.3616 8.5402 0.8214 2.09E-31 9.4129 8.4242 0.9887 5.40E-25 
CENPE 1062 
centromere protein E, 
312kDa [Source:HGNC 
Symbol;Acc:1856] 
8.2865 5.6933 2.5932 1.11E-76 8.4972 6.3121 2.1851 5.62E-45 
CENPF 1063 








protein 1 [Source:HGNC 
Symbol;Acc:16956] 
9.0233 7.2594 1.7639 1.89E-59 9.6456 7.6685 1.9771 6.46E-39 
PLK4 10733 
polo-like kinase 4 
[Source:HGNC 
Symbol;Acc:11397] 









9.4506 7.9167 1.5338 2.66E-58 9.9944 8.8320 1.1625 2.18E-30 
KIF2C 11004 
kinesin family member 
2C [Source:HGNC 
Symbol;Acc:6393] 






10.5868 8.8950 1.6917 1.09E-73 9.8943 7.7198 2.1744 3.89E-48 
CHEK1 1111 
CHK1 checkpoint 
homolog (S. pombe) 
[Source:HGNC 
Symbol;Acc:1925] 





10.3856 9.2152 1.1704 1.49E-49 10.5091 8.9004 1.6087 4.34E-37 
WDHD1 11169 
WD repeat and HMG-box 
DNA binding protein 1 
[Source:HGNC 
Symbol;Acc:23170] 
7.0907 5.4477 1.6430 4.16E-45 7.0289 6.0118 1.0172 6.38E-22 
FAM54A 113115
family with sequence 
similarity 54, member A 
[Source:HGNC 
Symbol;Acc:21115] 
7.9523 6.9721 0.9802 1.16E-36 7.8543 6.4716 1.3826 1.03E-32 
CDCA5 113130




7.9553 5.7082 2.2472 5.08E-51 8.5648 7.0744 1.4904 3.72E-36 
OIP5 11339 
Opa interacting protein 5 
[Source:HGNC 
Symbol;Acc:20300] 





RMI2, RecQ mediated 
genome instability 2, 
homolog (S. cerevisiae) 
[Source:HGNC 
Symbol;Acc:28349] 
9.3693 8.6630 0.7063 1.46E-22 8.3547 6.7954 1.5593 7.11E-37 
CKS2 1164 
CDC28 protein kinase 
regulatory subunit 2 
[Source:HGNC 
Symbol;Acc:2000] 
10.7549 8.9108 1.8441 6.33E-55 11.6929 9.8737 1.8193 8.17E-37 
E2F7 144455
E2F transcription factor 7 
[Source:HGNC 
Symbol;Acc:23820] 



















8.6408 6.6119 2.0289 8.05E-56 7.9289 5.8705 2.0584 9.44E-53 
SGOL2 151246
shugoshin-like 2 (S. 
pombe) [Source:HGNC 
Symbol;Acc:30812] 
8.1701 7.0805 1.0896 1.46E-22 8.9351 7.6153 1.3198 3.03E-22 
CDCA2 157313









establishment of cohesion 










10.7011 9.9093 0.7918 1.39E-47 11.0198 10.3755 0.6443 5.36E-18 
E2F1 1869 
E2F transcription factor 1 
[Source:HGNC 
Symbol;Acc:3113] 
7.8353 6.9487 0.8866 4.54E-17 7.6906 6.6499 1.0407 3.71E-18 
ECT2 1894 
epithelial cell 
transforming sequence 2 
oncogene [Source:HGNC 
Symbol;Acc:3155] 
10.0423 8.3374 1.7049 6.40E-71 10.0407 8.3038 1.7369 3.22E-43 
ZNF367 195828
zinc finger protein 367 
[Source:HGNC 
Symbol;Acc:18320] 
9.7429 8.3375 1.4055 6.30E-42 9.4195 7.9040 1.5155 3.13E-27 
TUBB 203068
tubulin, beta class I 
[Source:HGNC 
Symbol;Acc:20778] 
13.9398 13.2572 0.6826 1.36E-44 13.6300 12.9629 0.6671 1.83E-15 
EZH2 2146 
enhancer of zeste 
homolog 2 (Drosophila) 
[Source:HGNC 
Symbol;Acc:3527] 






8.2252 6.4856 1.7396 2.04E-46 8.4972 6.9794 1.5178 5.33E-33 
C11orf82 220042
chromosome 11 open 
reading frame 82 
[Source:HGNC 
Symbol;Acc:26351] 





spindle and kinetochore 
associated complex 
subunit 3 [Source:HGNC 
Symbol;Acc:20262] 













10.3370 7.9426 2.3944 2.33E-74 9.8806 7.6392 2.2414 1.79E-50 
FOXM1 2305 
forkhead box M1 
[Source:HGNC 
Symbol;Acc:3818] 






9.6573 8.7635 0.8938 1.32E-34 7.4632 6.5466 0.9167 2.26E-18 
NCAPH 23397 
non-SMC condensin I 
complex, subunit H 
[Source:HGNC 
Symbol;Acc:1112] 
7.9510 4.8045 3.1465 6.64E-90 7.2859 5.7983 1.4876 1.41E-29 
ORC6 23594 
origin recognition 
complex, subunit 6 
[Source:HGNC 
Symbol;Acc:17151] 
9.7295 9.0126 0.7169 3.82E-31 10.3432 8.8481 1.4951 4.50E-36 
POLA2 23649 
polymerase (DNA 
directed), alpha 2 (70kD 
subunit) [Source:HGNC 
Symbol;Acc:30073] 
8.4734 7.5124 0.9609 4.19E-30 8.4773 7.7554 0.7219 2.79E-19 
KIF4A 24137 
kinesin family member 
4A [Source:HGNC 
Symbol;Acc:13339] 





centromere protein I 
[Source:HGNC 
Symbol;Acc:3968] 
6.4015 5.2264 1.1751 2.93E-20 7.4870 6.2415 1.2455 2.78E-27 
ASPM 259266












7.6188 5.4477 2.1711 1.21E-48 7.3575 6.1274 1.2301 9.86E-27 
FBXO5 26271 
F-box protein 5 
[Source:HGNC 
Symbol;Acc:13584] 




interacting Ras-like 2 
[Source:HGNC 
Symbol;Acc:17898] 
9.4603 9.0071 0.4532 2.01E-19 9.3901 8.8732 0.5169 3.68E-12 
ATAD2 29028 
ATPase family, AAA 
domain containing 2 
[Source:HGNC 
Symbol;Acc:30123] 
8.4357 7.4092 1.0265 7.87E-39 9.6193 8.5442 1.0752 2.47E-20 
UBE2T 29089 
ubiquitin-conjugating 
enzyme E2T (putative) 
[Source:HGNC 
Symbol;Acc:25009] 
9.2444 7.5460 1.6984 2.32E-41 9.5929 7.7382 1.8547 1.67E-37 
RACGAP
1 29127 
Rac GTPase activating 
protein 1 [Source:HGNC 
Symbol;Acc:9804] 
10.9846 9.8163 1.1683 2.77E-54 11.1031 9.9679 1.1352 3.93E-28 
UHRF1 29128 
ubiquitin-like with PHD 
and ring finger domains 1 
[Source:HGNC 










11.8683 11.0698 0.7985 1.50E-34 11.1708 10.6416 0.5293 1.03E-08 
H2AFZ 3015 




12.9892 12.2821 0.7071 8.21E-58 13.4269 12.6859 0.7410 4.28E-30 
HMGB2 3148 
high mobility group box 2 
[Source:HGNC 
Symbol;Acc:5000] 














12.1976 11.3527 0.8449 8.95E-44 12.5020 11.8531 0.6489 5.38E-20 
BIRC5 332 




9.4652 6.1781 3.2871 8.35E-77 9.6955 6.7468 2.9487 5.52E-62 
ILF2 3608 
interleukin enhancer 
binding factor 2, 45kDa 
[Source:HGNC 
Symbol;Acc:6037] 
11.7139 11.1266 0.5874 4.30E-28 11.8184 11.3695 0.4489 5.31E-11 
ILF3 3609 
interleukin enhancer 
binding factor 3, 90kDa 
[Source:HGNC 






chromosome 5 open 
reading frame 34 
[Source:HGNC 
Symbol;Acc:24738] 
8.2333 7.1888 1.0446 1.42E-38 8.2807 7.2686 1.0121 3.87E-27 
KIF11 3832 
kinesin family member 11 
[Source:HGNC 
Symbol;Acc:6388] 
8.9035 7.2203 1.6832 2.06E-54 9.1539 7.3362 1.8176 2.63E-37 
CENPW 387103
centromere protein W 
[Source:HGNC 
Symbol;Acc:21488] 
8.6031 7.2550 1.3481 2.12E-51 9.4123 7.9588 1.4535 2.39E-36 
LMNB1 4001 lamin B1 [Source:HGNC Symbol;Acc:6637] 9.8493 7.9812 1.8681 3.77E-53 9.1698 7.7341 1.4357 1.24E-20 
MAD2L1 4085 
MAD2 mitotic arrest 
deficient-like 1 (yeast) 
[Source:HGNC 
Symbol;Acc:6763] 































9.7075 8.4588 1.2488 5.23E-26 9.6294 8.8383 0.7911 7.06E-15 
MKI67 4288 




8.6159 6.8940 1.7219 7.47E-56 8.4161 6.3936 2.0225 5.95E-43 
MYBL1 4603 
v-myb myeloblastosis 




9.0439 8.1040 0.9399 5.86E-25 9.2956 8.2243 1.0713 1.96E-16 
MYBL2 4605 
v-myb myeloblastosis 




8.1246 5.7072 2.4174 2.00E-62 7.3421 5.6987 1.6434 6.14E-25 
NEK2 4751 
NIMA (never in mitosis 
gene a)-related kinase 2 
[Source:HGNC 
Symbol;Acc:7745] 
8.8379 6.1252 2.7127 7.13E-64 7.0361 5.7707 1.2654 2.46E-26 
ORC1 4998 
origin recognition 
complex, subunit 1 
[Source:HGNC 
Symbol;Acc:8487] 
6.2915 4.5656 1.7259 2.08E-35 6.4233 5.7365 0.6868 3.30E-12 
NUSAP1 51203 
nucleolar and spindle 
associated protein 1 
[Source:HGNC 
Symbol;Acc:18538] 
11.1491 8.9112 2.2379 7.87E-73 11.2450 8.6978 2.5472 3.43E-56 
GTSE1 51512 
G-2 and S-phase 
expressed 1 
[Source:HGNC 










9.5406 7.2216 2.3190 1.34E-59 9.7598 7.1350 2.6247 4.34E-55 
GINS2 51659 




9.0754 6.7370 2.3384 1.33E-53 9.1096 7.3019 1.8076 8.30E-43 
PLK1 5347 
polo-like kinase 1 
[Source:HGNC 
Symbol;Acc:9077] 
8.1295 6.7781 1.3514 8.47E-46 7.3309 6.1888 1.1421 4.20E-21 
MIS18A 54069 
MIS18 kinetochore 
protein homolog A (S. 
pombe) [Source:HGNC 
Symbol;Acc:1286] 
9.1813 8.4135 0.7678 8.33E-27 9.1874 8.4653 0.7221 1.46E-14 
FAM64A 54478 
family with sequence 
similarity 64, member A 
[Source:HGNC 
Symbol;Acc:25483] 








6.6315 4.7157 1.9159 1.08E-42 6.7891 5.7972 0.9919 2.21E-19 
NCAPG2 54892 
non-SMC condensin II 
complex, subunit G2 
[Source:HGNC 
Symbol;Acc:21904] 









9.1873 8.5654 0.6218 1.32E-26 9.5048 8.8346 0.6702 3.84E-19 
C12orf48 55010 
chromosome 12 open 
reading frame 48 
[Source:HGNC 
Symbol;Acc:26074] 
6.4690 3.9608 2.5082 2.29E-47 6.7017 5.8005 0.9012 3.10E-18 
CDCA4 55038 











8.2003 7.0644 1.1359 1.29E-23 8.8429 7.5070 1.3359 2.30E-30 
CDCA8 55143 









8.5129 5.7006 2.8123 7.92E-58 8.1190 6.1331 1.9859 6.19E-46 
FANCI 55215 
Fanconi anemia, 
complementation group I 
[Source:HGNC 
Symbol;Acc:25568] 
9.5296 7.8888 1.6408 1.67E-60 9.4004 7.5609 1.8395 2.56E-42 
NEIL3 55247 
nei endonuclease VIII-
like 3 (E. coli) 
[Source:HGNC 
Symbol;Acc:24573] 
















7.4689 5.0035 2.4655 2.21E-45 7.2290 5.8255 1.4035 4.87E-24 
DEPDC1 55635 
DEP domain containing 1 
[Source:HGNC 
Symbol;Acc:22949] 
7.2267 4.6602 2.5666 1.48E-55 7.8686 5.8915 1.9771 1.55E-43 
ASF1B 55723 
ASF1 anti-silencing 




9.4123 8.1839 1.2284 2.23E-54 8.3880 6.8184 1.5696 7.68E-43 
DEPDC1
B 55789 
DEP domain containing 
1B [Source:HGNC 
Symbol;Acc:24902] 
7.8767 5.4267 2.4500 4.54E-59 7.8894 5.9075 1.9819 3.15E-40 
CENPN 55839 
centromere protein N 
[Source:HGNC 
Symbol;Acc:30873] 
7.7543 5.4521 2.3022 8.58E-52 8.7617 6.9215 1.8402 2.08E-42 
PBK 55872 
PDZ binding kinase 
[Source:HGNC 
Symbol;Acc:18282] 
10.1144 7.3776 2.7368 2.54E-67 10.7520 7.6417 3.1103 2.19E-55 
KIF15 56992 
kinesin family member 15 
[Source:HGNC 
Symbol;Acc:17273] 
8.9357 7.5387 1.3970 1.73E-51 8.9620 7.2289 1.7331 1.17E-40 
PTBP1 5725 
polypyrimidine tract 
binding protein 1 
[Source:HGNC 
Symbol;Acc:9583] 

















7.0620 6.4342 0.6278 3.04E-18 7.8545 7.0773 0.7772 6.70E-16 
RFC2 5982 
replication factor C 
(activator 1) 2, 40kDa 
[Source:HGNC 
Symbol;Acc:9970] 
9.6545 8.7627 0.8917 1.38E-45 9.9808 9.0754 0.9054 2.08E-23 
RFC3 5983 
replication factor C 
(activator 1) 3, 38kDa 
[Source:HGNC 
Symbol;Acc:9971] 
8.3840 7.4615 0.9225 2.93E-34 8.6236 7.7364 0.8873 1.66E-15 
RFC4 5984 
replication factor C 
(activator 1) 4, 37kDa 
[Source:HGNC 
Symbol;Acc:9972] 





10.6266 7.6172 3.0093 9.62E-64 10.2850 7.3752 2.9098 1.14E-60 
CENPK 64105 
centromere protein K 
[Source:HGNC 
Symbol;Acc:29479] 
9.2188 6.8485 2.3703 1.22E-55 9.2613 6.8406 2.4207 1.02E-50 
NCAPG 64151 
non-SMC condensin I 
complex, subunit G 
[Source:HGNC 
Symbol;Acc:24304] 











centromere protein H 
[Source:HGNC 
Symbol;Acc:17268] 







10.4298 9.9855 0.4443 9.46E-21 10.4099 10.1184 0.2915 4.11E-05 
BRCA2 675 
breast cancer 2, early 
onset [Source:HGNC 
Symbol;Acc:1101] 
6.8008 4.8048 1.9960 6.85E-39 6.9319 5.8815 1.0504 3.87E-24 
AURKA 6790 
aurora kinase A 
[Source:HGNC 
Symbol;Acc:11393] 
8.8679 7.0080 1.8599 1.88E-70 9.0387 7.2292 1.8095 1.43E-40 
TCF19 6941 
transcription factor 19 
[Source:HGNC 
Symbol;Acc:11629] 
8.9557 8.0280 0.9277 1.77E-37 8.1761 6.8675 1.3085 8.01E-28 
BUB1 699 





7.1234 4.2885 2.8349 1.46E-62 7.2005 5.7469 1.4535 7.10E-28 
BUB1B 701 
budding uninhibited by 
benzimidazoles 1 
homolog beta (yeast) 
[Source:HGNC 
Symbol;Acc:1149] 
9.5191 7.4934 2.0257 1.12E-73 9.4701 7.1502 2.3200 2.18E-51 
TK1 7083 
thymidine kinase 1, 
soluble [Source:HGNC 
Symbol;Acc:11830] 









9.7974 6.3258 3.4717 7.35E-48 10.2423 7.1752 3.0671 3.95E-47 
TTK 7272 
TTK protein kinase 
[Source:HGNC 
Symbol;Acc:12401] 
8.7681 6.5246 2.2435 1.60E-66 8.8309 6.5530 2.2779 2.05E-53 
TUBG1 7283 
tubulin, gamma 1 
[Source:HGNC 
Symbol;Acc:12417] 





11.8748 9.6850 2.1898 1.68E-71 11.9910 9.5496 2.4414 2.76E-55 
WHSC1 7468 
Wolf-Hirschhorn 
syndrome candidate 1 
[Source:HGNC 
Symbol;Acc:12766] 
9.2374 7.8143 1.4230 1.04E-35 8.4800 7.6085 0.8715 5.72E-18 
CENPM 79019 
centromere protein M 
[Source:HGNC 
Symbol;Acc:18352] 
6.5355 4.1767 2.3588 1.56E-46 7.8727 6.1098 1.7629 5.86E-32 
CENPO 79172 
centromere protein O 
[Source:HGNC 
Symbol;Acc:28152] 
8.7264 8.0795 0.6470 1.09E-22 8.5880 7.5993 0.9887 4.28E-25 
MLF1IP 79682 
MLF1 interacting protein 
[Source:HGNC 
Symbol;Acc:21348] 
10.2172 8.3036 1.9136 1.77E-69 10.5278 8.0311 2.4967 1.15E-55 
E2F8 79733 
E2F transcription factor 8 
[Source:HGNC 
Symbol;Acc:24727] 
7.5291 5.5919 1.9372 6.28E-41 7.3022 5.8106 1.4915 8.96E-32 
SHCBP1 79801 
SHC SH2-domain 
binding protein 1 
[Source:HGNC 
Symbol;Acc:29547] 





bora, aurora kinase A 
activator [Source:HGNC 
Symbol;Acc:24724] 








8.5072 7.5973 0.9099 2.12E-45 8.4604 7.7434 0.7170 7.31E-17 
FAM83D 81610 
family with sequence 
similarity 83, member D 
[Source:HGNC 
Symbol;Acc:16122] 
9.0276 8.0925 0.9350 1.88E-37 8.4979 6.6797 1.8181 2.89E-32 
CDT1 81620 
chromatin licensing and 
DNA replication factor 1 
[Source:HGNC 
Symbol;Acc:24576] 
7.3169 5.8423 1.4745 6.28E-29 6.4428 5.8364 0.6064 1.03E-09 
KIF18A 81930 
kinesin family member 
18A [Source:HGNC 
Symbol;Acc:29441] 
7.7208 5.6393 2.0816 2.38E-52 7.7269 6.0248 1.7021 1.53E-46 
CDCA3 83461 




8.4089 5.9979 2.4110 3.35E-65 9.3245 7.4663 1.8582 4.02E-48 
MXD3 83463 
MAX dimerization 
protein 3 [Source:HGNC 
Symbol;Acc:14008] 





















helicase 1 [Source:HGNC 
Symbol;Acc:20473] 
7.1677 5.4038 1.7640 8.69E-36 6.7973 5.7502 1.0471 2.27E-17 








10.4859 9.4511 1.0348 5.86E-46 10.7143 9.3686 1.3457 5.12E-34 
CCNA2 890 cyclin A2 [Source:HGNC Symbol;Acc:1578] 9.3812 7.8430 1.5381 6.41E-73 8.0304 6.0754 1.9550 8.53E-45 







9.3945 8.1190 1.2755 1.01E-63 9.1474 7.7565 1.3908 3.46E-38 
CCNF 899 cyclin F [Source:HGNC Symbol;Acc:1591] 5.9143 3.9436 1.9707 4.11E-30 7.5624 6.6209 0.9415 1.11E-20 
C15orf42 90381 
chromosome 15 open 
reading frame 42 
[Source:HGNC 
Symbol;Acc:28704] 
6.2177 4.1142 2.1035 9.67E-32 6.4914 5.8746 0.6167 7.21E-12 
PRC1 9055 








CCNB2 9133 cyclin B2 [Source:HGNC Symbol;Acc:1580] 9.8702 7.0807 2.7895 6.72E-79 10.0130 7.1047 2.9083 8.85E-63 
CENPL 91687 
centromere protein L 
[Source:HGNC 
Symbol;Acc:17879] 






11.2857 9.9657 1.3200 6.09E-63 11.5863 9.3091 2.2772 8.98E-55 
TRIP13 9319 




8.9281 7.6339 1.2943 1.53E-67 8.8892 7.1916 1.6976 3.21E-44 
HAUS8 93323 
HAUS augmin-like 
complex, subunit 8 
[Source:HGNC 
Symbol;Acc:30532] 
6.9398 5.0545 1.8853 5.53E-34 7.1935 6.1396 1.0538 2.84E-20 
KIF23 9493 
kinesin family member 23 
[Source:HGNC 
Symbol;Acc:6392] 
7.7676 4.8863 2.8812 3.62E-57 7.7023 5.8130 1.8894 4.68E-42 
ESPL1 9700 
extra spindle pole bodies 
homolog 1 (S. cerevisiae) 
[Source:HGNC 
Symbol;Acc:16856] 
8.6914 6.7135 1.9779 2.58E-63 8.2019 6.4806 1.7213 1.73E-44 
KNTC1 9735 
kinetochore associated 1 
[Source:HGNC 
Symbol;Acc:17255] 






10.9522 8.8394 2.1128 1.10E-71 11.3150 8.4052 2.9098 5.18E-60 
DLGAP5 9787 
discs, large (Drosophila) 
homolog-associated 
protein 5 [Source:HGNC 
Symbol;Acc:16864] 










6.1781 4.5535 1.6246 3.44E-31 6.4541 5.7623 0.6918 1.48E-13 
CDK1 983 
cyclin-dependent kinase 1 
[Source:HGNC 
Symbol;Acc:1722] 
10.3362 7.5994 2.7368 1.57E-63 11.3017 8.5033 2.7983 6.61E-53 
MELK 9833 
maternal embryonic 
leucine zipper kinase 
[Source:HGNC 
Symbol;Acc:16870] 
9.6807 6.9320 2.7487 7.90E-58 9.9502 7.3984 2.5518 2.31E-51 
GINS1 9837 




10.0007 8.3507 1.6500 9.39E-67 10.1735 8.5328 1.6407 2.73E-39 
CDC6 990 
cell division cycle 6 
homolog (S. cerevisiae) 
[Source:HGNC 
Symbol;Acc:1744] 
7.7926 6.6014 1.1912 3.24E-43 7.2167 5.8355 1.3812 4.23E-31 
CDC20 991 
cell division cycle 20 
homolog (S. cerevisiae) 
[Source:HGNC 
Symbol;Acc:1723] 
8.9181 6.1547 2.7634 1.02E-65 8.8269 6.2887 2.5382 8.78E-60 
KIF14 9928 
kinesin family member 14 
[Source:HGNC 
Symbol;Acc:19181] 
8.6156 6.1656 2.4500 5.57E-55 9.0334 6.5892 2.4441 2.19E-58 
CDC25C 995 
cell division cycle 25 
homolog C (S. pombe) 
[Source:HGNC 
Symbol;Acc:1727] 
7.3041 5.5986 1.7055 5.38E-40 7.3626 5.8443 1.5182 9.66E-36 
NEBL 10529 nebulette [Source:HGNC Symbol;Acc:16932] 7.7592 9.4798 -1.7207 2.64E-41 7.7998 9.4949 -1.6951 1.01E-23 





C5orf53 NA NA 10.2513 11.3361 -1.0848 3.77E-42 11.1165 11.8510 -0.7344 5.59E-15 
ELOVL7 79993 









Supplementary Table 3. Summary of Gene Set Enrichment Analysis (GSEA) results with FDR < 0.25. List of top-ranking stem cell-related genesets 
positively enriched with high PLK1 group of glioma patients. 
 






Genes down-regulated in NHEK cells (normal 
keratinocytes) by UV-B irradiation. 15 1.15586 1 
RIGGI_EWING_SARCOMA_PROGENITOR_DN 
Genes down-regulated in mesenchymal stem cells 
(MSC) engineered to express EWS-FLI1 fusion protein. 15 1.1429 1 
BENPORATH_CYCLING_GENES 
Embryonic stem cell signature related poorly 
differntiated glioblastoma and basal like subtypes 88 1.130648 0.9675661 
GRAHAM_CML_DIVIDING_VS_NORMAL_QU
IESCENT_UP 
Transcriptome related to CML stem cells and active 
chemokine signaling 65 1.06929 1 
BENPORATH_PROLIFERATION 
Identical embryonic stem cell profiles similar to poorly 
differentiated histological subtypes 44 1.06517 0.87619877 
ZHAN_MULTIPLE_MYELOMA_PR_UP 
Prolifearative signaling in the patient subgroups received 
stem cell transplants and high-dose therapy 33 1.0561 0.7729226 
GAL_LEUKEMIC_STEM_CELL_DN 
Down-regulated in leukemic stem cells (LSC), defined 
as CD34+CD38- cells from AML (acute myeloid 
leukemia patients) compared to the CD34+CD38+ cells. 
35 1.0178 0.7698555 
GRAHAM_CML_QUIESCENT_VS_NORMAL_Q
UIESCENT_UP 
Genes up-regulated in quiescent (G0) CD34+ cells 
isolated from peripheral blood of CML (chronic myeloid 
leukemia) patients compared to the quiescent cells from 
normal donors. 





Genes The 'core ESC-like gene module': genes 
coordinately up-regulated in a compendium of mouse 
embryonic stem cells (ESC) which are shared with the 
human ESC-like module 
56 0.8943225 0.84800136 
GRAHAM_NORMAL_QUIESCENT_VS_NORM
AL_DIVIDING_DN 
Genes down-regulated in quiescent vs dividing CD34+ 
[GeneID=8842] cells isolated from peripheral blood of 
normal donors. 
44 0.872945 0.82181394 
BENPORATH_ES_1 
Set 'ES exp1': genes overexpressed in human embryonic 
stem cells according to 5 or more out of 20 profiling 
studies. 
40 0.8567 0.7744122 
MUELLER_PLURINET 
Genes constituting the PluriNet protein-protein network 
shared by the pluripotent cells (embryonic stem cells, 
embryonical carcinomas and induced pluripotent cells). 
29 0.8417691 0.7328983 
BENPORATH_NANOG_TARGETS 
Set 'Nanog targets': genes upregulated and identified by 
ChIP on chip as Nanog transcription factor targets in 
human embryonic stem cells. 
24 0.6847 0.8637875 
BENPORATH_MYC_MAX_TARGETS 
Set 'Myc targets2': targets of c-Myc and Max identified 
by ChIP on chip in a Burkitt's lymphoma cell line; 
overlap set. 






Gene Target Primer sequence Product size (bp) 
NEK2 
Forward: 5’- CGA GAG CGA GCT CTC AAA GCA A -3’ 




Forward: 5’- GTG GTC GAA ATG GCT ATG GAG C -3’ 




Forward: 5’- AAG TCT GCT CCA GCT CCA CGA T-3’ 




Forward: 5’- GTT GCT GTG AGT CTA GGT ACT C -3’ 




Forward: 5’- CCT TTG CGA GCA GAA ACG GG –3’ 
Reverse: 5’- CTT AAC CTG TCG CTG CTC CAG –3’ 
 
181 




Forward: 5’- TCA GAC ACT GGC ATG GTG TT -3’ 
Reverse: 5’- AAG CCT AAG GGT GAA GAG GA -3’ 880 
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